

Address and Telephone

University of Florida
Department of Pharmacotherapy and Translational Research
College of Pharmacy
1345 Center Drive
MSB Room PG-27
PO Box 100486
Gainesville, FL 32610-0486 USA
Email: gong@cop.ufl.edu
Tel: (352) 273-6297
Fax: (352) 273-6121

EDUCATION/TRAINING

2018 – 2019 Graduate Certificate in Biomedical Informatics, University of Florida
2004 – 2005 Postdoctoral Fellow in Pharmacogenomics, University of Florida
1999 – 2004 Ph.D in Pharmaceutics, University of Florida
2001 – 2003 Master of Statistics, University of Florida
1996 – 1999 Master of Science in Pharmaceutics, West China University of Medical Sciences
(later merged with Sichuan University), Chengdu, Sichuan, CHINA

ACADEMIC POSITIONS/EMPLOYMENT

| | |
|----------------|---|
| 2016 – Present | Associate Professor, University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL |
| 2011 – 2016 | Research Associate Professor, University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL |
| 2005 – 2011 | Research Assistant Professor, University of Florida, College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL |
| 2004 – 2005 | Postdoctoral Fellow, University of Florida College of Pharmacy, Cardiovascular Pharmacogenomics, Department of Pharmacy Practice. Mentor: Julie A. Johnson, Pharm.D. |
| 1999 – 2004 | Teaching Assistant, Department of Pharmaceutics, University of Florida, Gainesville, FL. |
| 1996 – 1999 | Teaching Assistant, School of Pharmacy, West China University of Medical Sciences, Chengdu, Sichuan, P.R.CHINA |

HONORS AND AWARDS

Award for Outstanding Academic Achievement by an International Student, 2000
Travel Award, American Association of Pharmaceutical Scientist, 2003
Oral finalist, Research Showcase, University of Florida College of Pharmacy, 2004
Scholar-in-training Travel Award, Pharmacogenetics Research network, 2005
Best Poster, American Society of Clinical Pharmacology and Therapeutics, 2005
Presidential Trainee Award Winner, American Society for Clinical Pharmacology and Therapeutics, 2006
Open Access Award, University of Florida, 2012
NIGMS Bursary Award, 2013
Faculty Enhancement PROSPER Award, University of Florida College of Pharmacy, 2015
New England Journal of Medicine SPRINT Data Analysis Challenge Finalist, 2017
Outstanding Clinical Research Paper, College of Pharmacy, 2022

RESEARCH

ACTIVE RESEARCH SUPPORT

R01HG011800-01 (PI: Duarte) **Sep 2021 – June 2026**

NIH/NHLBI

‘Preemptive pharmacogenetic testing in medically underserved populations.’

The objectives are to identify PGx drug usage patterns in medically underserved patients, and assess the feasibility and effectiveness of preemptive PGx testing in this patient population.

Role: Co-investigator

R01HL151659 (PI: Gong) **Aug 2021 – July 2025**

NIH/NHLBI

‘A multi-omics evaluation of carfilzomib-related cardiotoxicity in multiple myeloma patients.’

The objectives of this proposal are to identify and validate metabolomic and pharmacogenomic biomarkers for carfilzomib-related HF in MM patients using a multi-omics approach and existing genome-wide association study (GWAS) data and/or whole-exome sequencing (WES) data in large electronic health record (EHR) systems.

Role: Principal Investigator

R01HL149752 (PI: Cavallari) **July 2020 – June 2025**

NIH/NHLBI

“Precision antiplatelet therapy after percutaneous coronary intervention”

The objective of this proposal is to elucidate the key factors that influence outcomes with a CYP2C19 genotype-guided precision medicine approach to DAPT.

Role: Co-Investigator

R01HD071779 (PI: Kwara) **July 2018 – June 2024**

NIH/NICHD

“Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children”

The objective of this proposal is to determine the PK of the first-line anti-TB and anti-HIV drugs, as well as characterize the factors associated with variable PK and drug-drug interactions in children in Ghana, West Africa.

Role: Co-Investigator

R01HD093612 (PI: Markowitz)

July 2018 – June 2023

NIH/NICHD

“Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD”

The objective of this proposal is to further identify and characterize genetic variants that affect CES1 expression and activity and reveal key associations between CES1 genotypes and the PK and pharmacodynamics (PD) of MPH in ADHD patients.

Role: Co-Investigator

COMPLETED RESEARCH SUPPORT

PROSPER Seed Award (MPI: Gong/Wang)

Aug 2022 - Sep 2023

UF College of Pharmacy

‘Determining the Underlying Mechanism of *TMSB10* Variant Association with Cardiotoxicity using Induced Pluripotent Stem Cells.’

The goal of this project is to determine the functional significance of the *TMSB10* variant in cardiomyocytes.

Role: Principal Investigator

R56DE030538 (PI: Gong)

Sep 2021 – Sep 2023

NIH/NIDCR

‘Toward a Precision Medicine Approach to Medication-related Osteonecrosis of the Jaw.’

The major goals of this proposal are to further validate pharmacogenomic markers that predispose patients to BP-related ONJ, to identify biomarkers for denosumab-related ONJ, and to create a predictive model for future clinical implementation of a Precision Medicine strategy for antiresorptive therapies.

Role: Principal Investigator

UF Research AI Research Catalyst Fund (Co-PIs: Lu & Gong)

Dec 2020 - Dec 2021

‘A Kernel Neural Network for High-dimensional Genomic Risk Prediction.’

The objectives of this proposal are to develop a kernel-based neural network (KNN) for high-dimensional risk prediction on large-scale genome data, and to use it in the collaborative research of studying a coronary artery disease (CAD) prediction model.

Role: Co-Principal Investigator

U01HG007269 (PI: Johnson)

Sep 2018 – June 2023

NIH/NHGRI

“Sparking Advancements in Genomic Medicine”

The objective of this proposal is to test the hypothesis that CYP2D6 genotype-guided pain management leads to improved patient reported outcomes for pain control and is cost-effective in a real-world setting.

Role: Co-Investigator

| | |
|---|------------------------------|
| CTSI COVID-19 Rapid-Response Research (PI: Gong) NIH/NCATS ‘Genomics and Pharmacogenomics of susceptibility and severity of COVID-19 in the UK Biobank.’ The objective of this project is to identify genetic, pharmacogenetic and nongenetic risk factors for susceptibility and severity of COVID-19 in UKB participants. Role: Principal Investigator | June 2020 - Dec 2020 |
| CTSI/UFII Big Data in Health Pilot Award (PI: Gong) NIH/NCATS ‘Toward prevention of cardiotoxicity in cancer: a multimodal approach leveraging genomics, images and clinical data.’ The goal of this project is to explore a novel approach to identify patients predisposed to cancer therapy induced cardiotoxicity through interrogation of pharmacogenomics, medical images and clinical factors linked in the electronic health records in the UK Biobank data. Role: Principal Investigator | June 2019 - May 2020 |
| CTSI Non-Patient Oriented Pilot Award (PI: Gong) NIH/NCATS ‘Cancer therapy-induced cardiotoxicity in the OneFlorida Consortium’ The goal of this project is to develop a computable phenotype for cancer drug-induced cardiotoxicity in electronic health records in order to evaluate these clinically significant adverse events in the real-world clinical settings of OneFlorida Clinical Research Consortium. Role: Principal Investigator | April 2018 - Oct 2019 |
| PROSPER Seed Award (PI: Gong) UF College of Pharmacy ‘Global Metabolomic Profiling of Proteasome Inhibitor Carfilzomib-Related Heart Failure in Multiple Myeloma Patients.’ The goal of this project is to identify baseline metabolomic biomarkers for carfilzomib-related heart failure in multiple myeloma patients using an untargeted metabolomics approach. Role: Principal Investigator | July 2019 - Sep 2020 |
| R24GM119977 (PI: Terada) NIH/NIGMS “A Stem Cell Tactic to Promote Personalized Medicine” The goal of this project is to establish a Pharmacogenomics induced pluripotent stem cells (iPSCs) Library and Service (PiLS) resource. Role: Co-Investigator | July 2016 – June 2019 |
| R01 DE019456 (PI: Shaddox) NIH/NIDCR “Mechanisms and Treatment Response of Aggressive Periodontitis in Children” | June 2014 – May 2019 |

The purpose of this study is to investigate genetic, epigenetic and immunological pathways responsible for the LPS hyper-inflammatory response seen in children with aggressive periodontitis.

Role: Co-Investigator

U01FD005235 (PI: Cavallari)

Sep 2014 – August 2018

NIH/FDA

“Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs”

The goal of this project is to provide pharmacokinetic and pharmacodynamic data to help the FDA better understand which factors should be considered in bioequivalence studies of metoprolol ER products.

Role: Co-Investigator

U01HG007269 (PI: Johnson)

May 2013 – April 2018

NIH/NHGRI

“Genomic Medicine Implementation: The Personalized Medicine Program”

This grant supports genomic medicine implementation. Its aims include an expansion of the UF Health Personalized Medicine Program, outreach to initiate genomic medicine implementation at two cardiology practice groups within Orlando Health, and at community hospitals that are part of the Florida State University Medical School network and to develop innovative educational programming for health sciences students, practitioners and patients.

Role: Co-investigator

U01 GM074492 (PIs: Johnson & Cooper-DeHoff)

August 2010 - July 2015

NIH/NIGMS

“Pharmacogenomic Evaluation of Antihypertensive Response (PEAR)”

This study aims to advance hypertension pharmacogenomics, focusing defining replicated genetic determinants of the antihypertensive and adverse metabolic effects of thiazide diuretics and beta-blockers, along with the genetic determinants of long term cardiovascular outcomes and new-onset diabetes with these same drugs. We also seek to define the mechanistic underpinnings of the genetic associations

Role: Co-investigator

U01 GM092655 (PI: Sadee)

August 2010 - July 2015

NIH/NIGMS

“Expression Genetics in Drug Therapy”

The purpose of this program is to identify the role of differential expression genetics as a source of genetic variability in drug response. Our role in the project is to test genetic associations of drug response in antihypertensive drug response datasets at the University of Florida.

Role: Co-investigator

R-238 (PI: Gong)

August 2014 – August 2015

Micromedic Technologies

“Genetic Risk Factors Associated with Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ) Occurrence”

This purpose of this grant is to identify genetic polymorphisms contributing to osteonecrosis of the Jaw in patients taking bisphosphonates using Whole Exome sequencing technology.

Role: Principal investigator

Lockheed Martin (PI: Conlon)

August 2014-August 2015

“Evaluation of quantum computation augmented machine learning algorithm for identifying pharmacogenomics biomarkers during adaptive clinical trials.”

Role: Co-investigator

R01 NS073346 (PI: Johnson)

March 2011 – Feb 2014

NIH/NINDS

“Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy”

Role: co-investigator

NIH/NHLBI RS&G service (PI: Gong)

Title: “Confirming Pharmacogenomics Signals for Antihypertensive Response in INVEST-GENES”

Role: Principal Investigator

K23HL081245 (PI: Blake)

August 2006 – July 2012

NIH/NHLBI

“Pharmacogenetic Studies of β_2 agonists in Asthma”

Role: co-mentor

RC2 GM092729-01 (PI: Kaddurah-Daouk)

October 2010 - September 2012

NIH/NIGMS

“Metabolomics Network for Drug Response Phenotype”

This grant is to support metabolomics analyses within the PEAR study population

Role: Co-investigator

R01 HL074730 (PI: Johnson)

September 2009 - August 2010

NIH/NHLBI

“Hypertension pharmacogenetics”

The aims of this study are to: 1) Determine SNPs in five genes relevant to calcium regulation and the calcium channel blocker response; 2) Determine *in vitro* functional consequences of discovered polymorphisms; 3) Determine association between sequence variability in relevant genes and antihypertensive response to verapamil; 4) Determine associations between genotype and outcomes (death, myocardial infarction, stroke) for patients taking atenolol, verapamil, trandolapril and hydrochlorothiazide; 5) Determine the role of assessing population stratification and ancestral proportions using genetic markers in pharmacogenetic studies.

Role: Co-investigator

U01 GM074492 (PI: Johnson)

September 2005 - August 2010

NIH/NIGMS

“Pharmacogenomic Evaluation of Antihypertensive Response (PEAR)”

The aims of this study are to: identify genetic predictors of the antihypertensive and adverse metabolic responses to a β -blocker (atenolol) and a thiazide diuretics (HCTZ), first by testing 7

SNPs in each of 70 candidate genes for genetic association with: antihypertensive responses to monotherapy (Aim 1a), addition of a second drug to monotherapy (Aim 1b), and combination therapy (Aim 1c); and adverse metabolic responses to mono and combination therapy (Aim 1d). Aim 2 seeks to identify genetic associations with these same responses through testing of 20,000 putative functional SNPs that span the human genome.

Role: co-investigator

R-238 (PI: Katz)**September 2008 - September 2010**

Micromedic Technologies

"Pharmacogenetics, pharmacokinetics and bone markers"

Pharmacogenomics study of Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ) "

Role: Co-investigator

BOOK CHAPTERS

Sullivan S, **Gong Y**, Hughes JA. Cationic liposomes in gene delivery. *Liposomes, a practical approach, second edition*. Oxford University Press; 2002:289-301.

Gong Y, McDonough CW, Padmanabhan S, Johnson JA. Hypertension Pharmacogenomics. *Handbook of Pharmacogenomics and Stratified Medicine*. Academic Press Inc; 2014: 747-778.

ORIGINAL PUBLICATIONS (IN REVERSE CHRONOLOGICAL ORDER):

<http://www.ncbi.nlm.nih.gov/sites/myncbi/yan.gong.1/bibliography/40498735/public/?sort=date&direction=descending>

1. Nahid NA, McDonough CW, Wei Y, Cicali E, **Gong Y**, Fillingim R, Johnson JA. Use of CYP2D6 inhibitors with CYP2D6 Opioids: Association with emergency department visits for pain. *Submitted to JAMA*. 2024.
2. Thomas CD, Franchi F, Rossi J, Keeley E, Anderson RD, Beitelshes AL, Duarte JD, Ortega-Paz L, **Gong Y**, Kerensky RA, Kulick N, McDonough C, Nguyen A, Wang Y, Winget M, Yang WE, Johnson JA, Winterstein A, Stouffer GA, Angiolillo DJ, Lee CR, Cavallari LH. Effectiveness of clopidogrel versus alternative P2Y12 Inhibitors based on the ABCD-GENE score: a real-world investigation. *Submitted to J Am Coll Cardiol*, 2024.
3. Huang Y, Lteif C, Dumeny L, Yang G, Leibold P, Guerra L, Hammond H, Arwood M, McDonough C, **Gong Y**, Desai A, Cavallari L, Duarte J. Genome-wide association study identifies *PDE10A* and *PCDH7* risk loci for mortality in an ancestrally diverse heart failure population. *Submitted*, 2024.
4. Cicali EJ, Eddy E, **Gong Y**, Elchynski AL, del Aguila KP, Basha T, Daily KC, Dickson L, Fischer S, Hastings-Monari E, Jones D, Ramnaraign BH, Deremer DL, George TJ, Cooper-DeHoff RM. Implementation of a Pharmacogenetic Panel-based Test for Supportive Care Therapy in an Adult Oncology Clinic. *Submitted*, 2024.
5. Shabnaz S, Nguyen TN, Williams R, Rubinstein SM, Garrett TJ, Tantawy M, Fradley MG, Alomar M, Shain K, Baz RC, Lu Q, Lenihan D, Cornell RF, **Gong Y**. Metabolomic signatures of carfilzomib-related cardiotoxicity in multiple myeloma patients. *submitted*, 2024.

6. Bruno KA, Fradley MG, Brown S-A, Guha A, Cousin L, Guo Y, O'Dell WG, Smuder WJ, Yang S, Braithwaite D, Pepine CJ, **Gong Y**. Racial/Ethnic Disparities, Artificial Intelligence, and Cutting-edge Research: Proceedings from the 2023 Florida Cardio-Oncology Symposium. *Am Heart J Plus*. Under Review. 2024.
7. Bruno KA, O'Dell WG, Tantawy M, Casson CL, Ferrall-Fairbanks MC, DeRemer DL, Dungan JR, Nguyen BL, Roumi NH, Shabnaz S, Smuder AJ, Vilaro MJ, Norton N, Fairweather D, **Gong Y**. Research summary of poster presentations at the 2023 Florida Cardio-Oncology Symposium. *Am Heart J Plus*. 2024; 37:100348. doi: 10.1016/j.ahjo.2023.100348.
8. Mosley SA, Cicali E, Del Cueto A, Portman DG, Donovan KA, **Gong Y**, Langae T, Gopalan P, Schmit J, Starr JS, Silver N, Chang YD, Rajasekhara S, Smith JE, Soares HP, Clare-Salzler M, Starostik P, George TJ, McLeod HL, Fillingim RB, Hicks JK, Cavallari LH. CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial. *Pharmacotherapy*. 2023 Sep 12. doi: 10.1002/phar.2875. Epub ahead of print. PMID: 37698371.
9. Tantawy M, Yang G, Algubelli RR, DeAvila G, Rubinstein SM, Cornell RF, Fradley MG, Siegel EM, Hampton OA, Silva AS, Lenihan D, Shain KH, Baz RC, **Gong Y**. Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. *Front Cardiovasc Med*. 2023;10:1181806. doi: 10.3389/fcvm.2023.1181806. eCollection 2023. PubMed PMID: 37408649; PubMed Central PMCID: PMC10319068.
10. Fradley MG, Nguyen NK, Madnick D, Chen Y, DeMichele A, Makhlin I, Dent S, Lefebvre B, Carver J, Upshaw J, DeRemer D, Ky B, Guha A, **Gong Y**. Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer. *J Am Heart Assoc*. 2023 Jun 20;12(12):e029361. doi: 10.1161/JAHA.123.029361. Epub 2023 Jun 10. PubMed PMID: 37301767.
11. DeRemer DL, Nguyen NK, Guha A, Ahmad FS, Cooper-DeHoff RM, Pepine CJ, Fradley MG, **Gong Y**. Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline-Based Chemotherapy. *J Am Heart Assoc*. 2023 May 16;12(10):e027981. doi: 10.1161/JAHA.122.027981. Epub 2023 May 9. PubMed PMID: 37158063; PubMed Central PMCID: PMC10227284.
12. Cavallari LH, Limdi NA, Beitelshes AL, Lee JC, Duarte JD, Franchi F, Tuteja S, Giri J, Empey PE, Kreutz RP, Skaar TC, Allen JM, Coons JC, **Gong Y**, McDonough CW, Stevenson JM, Thomas CD, Johnson JA, Stouffer GA, Angiolillo DJ, Lee CR. Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y₁₂ Inhibitor Prescribing After Percutaneous Coronary Intervention. *Clin Pharmacol Ther*. 2023 Mar;113(3):615-623. doi: 10.1002/cpt.2776. Epub 2022 Nov 19. PubMed PMID: 36306392; PubMed Central PMCID: PMC9957848.
13. Yang G, Williams R, Wang L, Farhadfar N, Chen Y, Loiacono AT, Bian J, Holliday LS, Katz J, **Gong Y**. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium. *J Bone Miner Res*. 2022 Dec;37(12):2466-2471. doi: 10.1002/jbmr.4708. Epub 2022 Oct 5. PubMed PMID: 36151778; PubMed Central PMCID: PMC9772085.

14. Guha A, **Gong Y**, DeRemer D, Owusu-Guha J, Dent SF, Cheng RK, Weintraub NL, Agarwal N, Fradley MG. [Cardiometabolic Consequences of Targeted Anticancer Therapies.](#) *J Cardiovasc Pharmacol.* 2022 Oct 1;80(4):515-521. doi: 10.1097/FJC.0000000000001149. PubMed PMID: 34654781; PubMed Central PMCID: PMC8977391.
15. Cavallari LH, Cicali E, Wiisanen K, Fillingim RB, Chakraborty H, Myers RA, Blake KV, Asiyambola B, Baye JF, Bronson WH, Cook KJ, Elwood EN, Gray CF, **Gong Y**, Hines L, Kannry J, Kucher N, Lynch S, Nguyen KA, Obeng AO, Pratt VM, Prieto HA, Ramos M, Sadeghpour A, Singh R, Rosenman M, Starostik P, Thomas CD, Tillman E, Dexter PR, Horowitz CR, Orlando LA, Peterson JF, Skaar TC, Van Driest SL, Volpi S, Voora D, Parvataneni HK, Johnson JA. [Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.](#) *Clin Transl Sci.* 2022 Oct;15(10):2479-2492. doi: 10.1111/cts.13376. Epub 2022 Aug 4. PubMed PMID: 35899435; PubMed Central PMCID: PMC9579394.
16. Mehanna M, McDonough CW, Smith SM, **Gong Y**, Gums JG, Chapman AB, Johnson JA, Cooper-DeHoff RM. [Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.](#) *Metabolites.* 2022 Aug 24;12(9). doi: 10.3390/metabo12090783. PubMed PMID: 36144188; PubMed Central PMCID: PMC9506508.
17. Armstrong ND, Srinivasasainagendra V, Chekka LMS, Nguyen NHK, Nahid NA, Jones AC, Tanner RM, Hidalgo BA, Limdi NA, Claas SA, **Gong Y**, McDonough CW, Cooper-DeHoff RM, Johnson JA, Tiwari HK, Arnett DK, Irvin MR. [Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments \(GenHAT\) Study.](#) *Genes (Basel).* 2022 Jul 15;13(7). doi: 10.3390/genes13071260. PubMed PMID: 35886043; PubMed Central PMCID: PMC9319619.
18. Thomas CD, Franchi F, Keeley EC, Rossi JS, Winget M, David Anderson R, Dempsey AL, **Gong Y**, Gower MN, Kerensky RA, Kulick N, Malave JG, McDonough CW, Mulrenin IR, Starostik P, Beitelshes AL, Johnson JA, Stouffer GA, Winterstein AG, Angiolillo DJ, Lee CR, Cavallari LH. [Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.](#) *Clin Pharmacol Ther.* 2022 Jul;112(1):146-155. doi: 10.1002/cpt.2612. Epub 2022 May 2. PubMed PMID: 35429163; PubMed Central PMCID: PMC9233085.
19. Mosley SA, Kim S, El Rouby N, Lingineni K, Esteban VV, **Gong Y**, Chen Y, Estores D, Feng K, Kim H, Kinjo M, Langaaee T, Li Z, Schmidt SOF, Johnson JA, Frye RF, Fang LL, Zhao L, Binkley PF, Schmidt S, Cavallari LH. [A randomized, cross-over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence.](#) *Clin Transl Sci.* 2022 Jul;15(7):1764-1775. doi: 10.1111/cts.13294. Epub 2022 May 21. PubMed PMID: 35488487; PubMed Central PMCID: PMC9283731.
20. Schillemans T, Tragante V, Maitusong B, Gigante B, Cresci S, Laguzzi F, Vikström M, Richards M, Pilbrow A, Cameron V, Foco L, Doughty RN, Kuukasjärvi P, Allayee H, Hartiala JA, Tang WHW, Lyytikäinen LP, Nikus K, Laurikka JO, Srinivasan S, Mordi IR, Trompet S, Kraaijeveld A, van Setten J, Gijsberts CM, Maitland-van der Zee AH, Saely CH, **Gong Y**, Johnson JA, Cooper-DeHoff RM, Pepine CJ, Casu G, Leiherer A, Drexel H, Horne BD, van der Laan SW, Marziliano N, Hazen SL, Sinisalo J, Kähönen M, Lehtimäki T, Lang CC, Burkhardt

- R, Scholz M, Jukema JW, Eriksson N, Åkerblom A, James S, Held C, Hagström E, Spertus JA, Algra A, de Faire U, Åkesson A, Asselbergs FW, Patel RS, Leander K. [Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis](#). *Front Physiol.* 2022;13:909870. doi: 10.3389/fphys.2022.909870. eCollection 2022. PubMed PMID: 35812313; PubMed Central PMCID: PMC9260705.
21. Zhang D, Leeuwenburgh C, Zhou D, **Gong Y**, Pahor M, Licht JD, Braithwaite D. [Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease-Specific Death in Cancer Survivors](#). *JAMA Netw Open*. 2022 Jun 1;5(6):e2218183. doi: 10.1001/jamanetworkopen.2022.18183. PubMed PMID: 35731518.
22. Yu Z, Yang X, Chen Y, Fang R, Hogan WR, **Gong Y**, Wu Y. Identify Cancer Patients at Risk for Heart Failure using Electronic Health Record and Genetic Data. 2022 *IEEE 10th International Conference on Healthcare Informatics (ICHI)*, 2022, pp. 138-142, doi: 10.1109/ICHI54592.2022.00032.
23. Das A, Dasgupta S, **Gong Y**, Shah UA, Fradley MG, Cheng RK, Roy B, Guha A. [Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials](#). *Hematol Oncol*. 2021 Dec 23;. doi: 10.1002/hon.2959. [Epub ahead of print] PubMed PMID: 34940983.
24. Yang G, Singh S, McDonough CW, Lamba JK, Hamadeh I, Holliday LS, Wang D, Katz J, Lakatos PA, Balla B, Kosa JP, Pelliccioni GA, Price DK, Van Driest SL, Figg WD, Langaaee T, Moreb JS, **Gong Y**. [Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw](#). *Clin Pharmacol Ther*. 2021 Dec;110(6):1558-1569. doi: 10.1002/cpt.2397. Epub 2021 Aug 31. PubMed PMID: 34390503; PubMed Central PMCID: PMC8630710.
25. Mehanna M, McDonough CW, Smith SM, **Gong Y**, Gums JG, Chapman AB, Johnson JA, McIntyre L, Cooper-DeHoff RM. [Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients](#). *Metabolites*. 2021 Sep 21;11(9). doi: 10.3390/metabo11090645. PubMed PMID: 34564461; PubMed Central PMCID: PMC8466669.
26. McDonough CW, Warren HR, Jack JR, Motsinger-Reif AA, Armstrong ND, Bis JC, House JS, Singh S, El Rouby NM, **Gong Y**, Mychaleckyj JC, Rotroff DM, Benavente OR, Caulfield MJ, Doria A, Pepine CJ, Psaty BM, Glorioso V, Glorioso N, Hiltunen TP, Kontula KK, Arnett DK, Buse JB, Irvin MR, Johnson JA, Munroe PB, Wagner MJ, Cooper-DeHoff RM. [Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies](#). *Clin Pharmacol Ther*. 2021 Sep;110(3):723-732. doi: 10.1002/cpt.2355. Epub 2021 Aug 15. PubMed PMID: 34231218; PubMed Central PMCID: PMC8672325.
27. Langaaee T, Al-Shaer MH, **Gong Y**, Lima E, Antwi S, Enimil A, Dompreh A, Yang H, Alghamdi WA, Wiesner L, Peloquin CA, Kwara A. [Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection](#). *Infect Genet Evol*. 2021 Aug;92:104856. doi: 10.1016/j.meegid.2021.104856. Epub 2021 Apr 8. PubMed PMID: 33839311; PubMed Central PMCID: PMC8636019.

28. Schunk SJ, Kleber ME, März W, Pang S, Zewinger S, Triem S, Ege P, Reichert MC, Krawczyk M, Weber SN, Jaumann I, Schmit D, Sarakpi T, Wagenpfeil S, Kramann R, Boerwinkle E, Ballantyne CM, Grove ML, Tragante V, Pilbow AP, Richards AM, Cameron VA, Doughty RN, Dubé MP, Tardif JC, Feroz-Zada Y, Sun M, Liu C, Ko YA, Quyyumi AA, Hartiala JA, Tang WHW, Hazen SL, Allayee H, McDonough CW, **Gong Y**, Cooper-DeHoff RM, Johnson JA, Scholz M, Teren A, Burkhardt R, Martinsson A, Smith JG, Wallentin L, James SK, Eriksson N, White H, Held C, Waterworth D, Trompet S, Jukema JW, Ford I, Stott DJ, Sattar N, Cresci S, Spertus JA, Campbell H, Tierling S, Walter J, Ampofo E, Niemeyer BA, Lipp P, Schunkert H, Böhm M, Koenig W, Fliser D, Laufs U, Speer T. [Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.](#) *Eur Heart J.* 2021 May 7;42(18):1742-1756. doi: 10.1093/eurheartj/ehab107. PubMed PMID: 33748830.
29. Tantawy M, Chekka LM, Huang Y, Garrett TJ, Singh S, Shah CP, Cornell RF, Baz RC, Fradley MG, Waheed N, DeRemer DL, Yuan L, Langae TY, March K, Pepine CJ, Moreb JS, **Gong Y**. [Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis.](#) *Front Cardiovasc Med.* 2021;8:645122. doi: 10.3389/fcvm.2021.645122. eCollection 2021. PubMed PMID: 33996940; PubMed Central PMCID: PMC8116486.
30. Thomas CD, Parvataneni HK, Gray CF, Deen JT, Prieto HA, Pulido LF, Elsey AR, Elwood EN, Starostik P, **Gong Y**, Fillingim RB, Johnson JA, Cavallari LH. [A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.](#) *Genet Med.* 2021 Apr;23(4):621-628. doi: 10.1038/s41436-020-01050-4. Epub 2021 Jan 8. PubMed PMID: 33420349; NIHMSID:NIHMS1663578.
31. Dasa O, Smith SM, Howard G, Cooper-DeHoff RM, **Gong Y**, Handberg E, Pepine CJ. [Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.](#) *JAMA Netw Open.* 2021 Apr 1;4(4):e218418. doi: 10.1001/jamanetworkopen.2021.8418. PubMed PMID: 33914047.
32. Waheed N, Fradley MG, DeRemer D, Mahmoud A, Shah CP, Langae TY, Lipori GP, March K, Pepine CJ, Cooper-DeHoff RM, Wu Y, **Gong Y**. [Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center.](#) *Cardiooncology.* 2021 Mar 18;7(1):10. doi: 10.1186/s40959-021-00097-9. PubMed PMID: 33736707; PubMed Central PMCID: PMC7977591.
33. Lee CR, Thomas CD, Beitelshes AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, **Gong Y**, Kreutz RP, McDonough CW, Stevenson JM, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA, Cavallari LH. [Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.](#) *Clin Pharmacol Ther.* 2021 Mar;109(3):705-715. doi: 10.1002/cpt.2039. Epub 2020 Oct 2. PubMed PMID: 32897581; PubMed Central PMCID: PMC7902344.
34. Mehanna M, Chen YE, **Gong Y**, Handberg E, Roth B, De Leon J, Smith SM, Harrell JG, Cooper-DeHoff RM. [Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity](#)

- Testing. *Clin Transl Sci.* 2021 Mar;14(2):617-624. doi: 10.1111/cts.12922. Epub 2020 Nov 30. PubMed PMID: 33142006; PubMed Central PMCID: PMC7993275.
35. Bargal SA, Kight JN, Augusto de Oliveira F, Shahin MH, Langaee T, **Gong Y**, Hamadeh IS, Cooper-DeHoff RM, Cavallari LH. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans. *Clin Transl Sci.* 2021 Mar;14(2):492-496. doi: 10.1111/cts.12939. Epub 2020 Dec 16. PubMed PMID: 33278335; PubMed Central PMCID: PMC7993290.
36. Yang G, Collins JM, Rafiee R, Singh S, Langaee T, McDonough CW, Holliday LS, Wang D, Lamba J, Kim YS, Pelliccioni GA, Vaszilko M, Kosa JP, Balla B, Lakatos PA, Katz J, Moreb J, **Gong Y**. SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw. *J Bone Miner Res.* 2021 Feb;36(2):347-356. doi: 10.1002/jbmr.4185. Epub 2020 Oct 23. PubMed PMID: 32967053.
37. Tantawy M, Pamittan FG, Singh S, **Gong Y**. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity. *Clin Transl Sci.* 2021 Jan;14(1):36-46. doi: 10.1111/cts.12857. Epub 2020 Aug 28. PubMed PMID: 32770710.
38. Arwood MJ, McDonough CW, Cavallari LH, Elsey AR, Frye RF, **Gong Y**, Langaee T, Johnson JA, Wiisanen K. Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical Pharmacogenetics. *J Am Coll Clin Pharm.* 2020. <https://doi.org/10.1002/jac5.1335>
39. Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee TY, **Gong Y**, Wang D, Schmidt SO, Binkley PF, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman AB, Cooper-DeHoff RM, Gums JG, Hamadeh IS, Zhao L, Schmidt S, Frye RF, Johnson JA, Cavallari LH. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. *CPT Pharmacometrics Syst Pharmacol.* 2020 Dec;9(12):678-685. doi: 10.1002/psp4.12563. Epub 2020 Nov 3. PubMed PMID: 33067866; PubMed Central PMCID: PMC7762806.
40. Sava RI, Smith SM, Chen Y, Taha Y, **Gong Y**, Keeley EC, Cooper-Dehoff RM, Pepine CJ, Handberg EM. Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events - An analysis from INVEST☆. *Int J Cardiol Hypertens.* 2020 Dec;7:100052. doi: 10.1016/j.ijchy.2020.100052. eCollection 2020 Dec. PubMed PMID: 33817619; PubMed Central PMCID: PMC8009246.
41. Keeley EC, Villanueva M, Chen YE, **Gong Y**, Handberg EM, Smith SM, Pepine CJ, Cooper-DeHoff RM. Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease. *J Clin Hypertens (Greenwich).* 2020 Nov;22(11):1987-1992. doi: 10.1111/jch.14037. Epub 2020 Sep 20. PubMed PMID: 32951360; PubMed Central PMCID: PMC8029864.
42. Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, **Gong Y**, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. *Pharmacogenomics J.* 2020 Oct;20(5):724-735. doi: 10.1038/s41397-020-0162-5. Epub 2020 Feb 11. PubMed PMID: 32042096; PubMed Central PMCID: PMC7417282.

43. Mahmoodi BK, Tragante V, Kleber ME, Holmes MV, Schmidt AF, McCubrey RO, Howe LJ, Direk K, Allayee H, Baranova EV, Braund PS, Delgado GE, Eriksson N, Gijsberts CM, **Gong Y**, Hartiala J, Heydarpour M, Pasterkamp G, Kotti S, Kuukasjärvi P, Lenzini PA, Levin D, Lyytikäinen LP, Muehlschlegel JD, Nelson CP, Nikus K, Pilbrow AP, Wilson Tang WH, van der Laan SW, van Setten J, Vilmundarson RO, Deanfield J, Deloukas P, Dudbridge F, James S, Mordi IR, Teren A, Bergmeijer TO, Body SC, Bots M, Burkhardt R, Cooper-DeHoff RM, Cresci S, Danchin N, Doughty RN, Grobbee DE, Hagström E, Hazen SL, Held C, Hoefer IE, Hovingh GK, Johnson JA, Kaczor MP, Kähönen M, Klungel OH, Laurikka JO, Lehtimäki T, Maitland-van der Zee AH, McPherson R, Palmer CN, Kraaijeveld AO, Pepine CJ, Sanak M, Sattar N, Scholz M, Simon T, Spertus JA, Stewart AFR, Szczeklik W, Thiery J, Visseren FLJ, Waltenberger J, Richards AM, Lang CC, Cameron VA, Åkerblom A, Pare G, März W, Samani NJ, Hingorani AD, Ten Berg JM, Wallentin L, Asselbergs FW, Patel RS. [Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data.](#) *Circulation.* 2020 Aug 11;142(6):546-555. doi: 10.1161/CIRCULATIONAHA.119.045526. Epub 2020 Jul 13. PubMed PMID: 32654539; PubMed Central PMCID: PMC7493828.
44. Yang X, **Gong Y**, Waheed N, March K, Bian J, Hogan WR, Wu Y. [Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods.](#) *AMIA Annu Symp Proc.* 2019;2019:933-941. eCollection 2019. PubMed PMID: 32308890; PubMed Central PMCID: PMC7153053.
45. Magvanjav O, Cooper-Dehoff RM, McDonough CW, **Gong Y**, Hogan WR, Johnson JA. [Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.](#) *Am J Hypertens.* 2020 Apr 1;33(4):316-324. doi: 10.1093/ajh/hpz196. PubMed PMID: 31853537; PubMed Central PMCID: PMC7109351.
46. Elgendi IY, Hill JA, Szady AD, **Gong Y**, Cooper-DeHoff RM, Pepine CJ. [Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure.](#) *ESC Heart Fail.* 2020 Feb;7(1):123-129. doi: 10.1002/ehf2.12534. Epub 2019 Dec 15. PubMed PMID: 31840441; PubMed Central PMCID: PMC7083485.
47. Archampong T, Ojewale O, Bears K, Chen Y, Lartey M, Sagoe KW, Obo-Akwa A, **Gong Y**, Langaa T, Kwara A. [Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.](#) *J Acquir Immune Defic Syndr.* 2019 Dec 1;82(4):421-425. doi: 10.1097/QAI.0000000000002136. PubMed PMID: 31335591; PubMed Central PMCID: PMC6817383.
48. Singh S, McDonough CW, **Gong Y**, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. [Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.](#) *Sci Rep.* 2019 Nov 21;9(1):17323. doi: 10.1038/s41598-019-53345-5. PubMed PMID: 31754133; PubMed Central PMCID: PMC6872535.

49. Shahin MH, Rouby NE, Conrado DJ, Gonzalez D, **Gong Y**, Lohmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. β_2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β -Blockers: Evidence From 3 Clinical Studies. *J Clin Pharmacol.* 2019 Nov;59(11):1462-1470. doi: 10.1002/jcph.1443. Epub 2019 May 14. PubMed PMID: 31090079; PubMed Central PMCID: PMC6773496.
50. Cunningham PN, Wang Z, Grove ML, Cooper-DeHoff RM, Beitelshes AL, **Gong Y**, Gums JG, Johnson JA, Turner ST, Boerwinkle E, Chapman AB. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. *PLoS One.* 2019;14(9):e0221957. doi: 10.1371/journal.pone.0221957. eCollection 2019. PubMed PMID: 31532792; PubMed Central PMCID: PMC6750571.
51. Singh S, El Rouby N, McDonough CW, **Gong Y**, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans. *Clin Transl Sci.* 2019 Sep;12(5):497-504. doi: 10.1111/cts.12643. Epub 2019 Jun 4. PubMed PMID: 31033190; PubMed Central PMCID: PMC6742943.
52. Singh S, Warren HR, Hiltunen TP, McDonough CW, El Rouby N, Salvi E, Wang Z, Garofalidou T, Fyhrquist F, Kontula KK, Glorioso V, Zaninello R, Glorioso N, Pepine CJ, Munroe PB, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, **Gong Y**, Cooper-DeHoff RM. Genome-Wide Meta-Analysis of Blood Pressure Response to β_1 -Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). *J Am Heart Assoc.* 2019 Aug 20;8(16):e013115. doi: 10.1161/JAHA.119.013115. Epub 2019 Aug 19. PubMed PMID: 31423876; PubMed Central PMCID: PMC6759913.
53. Smith DM, Weitzel KW, Elsey AR, Langae T, **Gong Y**, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, Johnson JA, Cavallari LH. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. *Genet Med.* 2019 Aug;21(8):1842-1850. doi: 10.1038/s41436-018-0431-8. Epub 2019 Jan 23. PubMed PMID: 30670877; PubMed Central PMCID: PMC6650382.
54. Harris TH, Wallace MR, Huang H, Li H, Mohiuddeen A, **Gong Y**, Kompotiati T, Harrison P, Aukhil I, Shaddox LM. Association of P2RX7 functional variants with localized aggressive periodontitis. *J Periodontal Res.* 2019 Jul 10;. doi: 10.1111/jre.12682. [Epub ahead of print] PubMed PMID: 31292966.
55. Mehanna M, Wang Z, **Gong Y**, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, Cooper-DeHoff RM. Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. *Am J Hypertens.* 2019 Jun 11;32(7):668-675. doi: 10.1093/ajh/hpz022. PubMed PMID: 30753254; PubMed Central PMCID: PMC6558666.

56. El Rouby N, McDonough CW, **Gong Y**, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Bradford Y, Crawford DC, Ritchie MD, Gitzendanner MA, Takahashi A, Tanaka T, Kubo Michiaki, Pepine CJ, Cooper-DeHoff RM, Benavente OR, Shuldiner AR, Johnson JA. Genome-wide Association Analysis of Common Genetic Variants of Resistant Hypertension. *Pharmacogenomics J.* 2019 Jun;19(3):295-304. doi: 10.1038/s41397-018-0049-x. Epub 2018 Sep 20. PubMed PMID: 30237584; PubMed Central PMCID: PMC6426691.
57. Chamberlain AM, **Gong Y**, MaAuliffe K, Bian J, Song W, Liton MF, Fonseca V, Price-Haywood E, Guhl Em King JB, Shah RU, Puro J, Shenkman E, Pawloski PA, Margolis KL, Hernandez A, Cooper-DeHoff RM. PCSK9 Inhibitor Use in the Real World: Data from the National Patient Centered Research Network (PCORNet). *J Am Heart Assoc.* 2019 May 7;8(9):e011246. doi: 10.1161/JAHA.118.011246. PubMed PMID: 31020929.
58. Yang G, Singh S, Chen Y, Hamadeh IH, Langae T, McDonough CW, Holliday LS, Lamba J, Moreb JS, Katz J, **Gong Y**. Pharmacogenomics of Osteonecrosis of the Jaw. *Bone.* 2019 Apr 22. pii: S8756-3282(19)30146-2. doi: 10.1016/j.bone.2019.04.010. [Epub ahead of print] Review. PubMed PMID: 31022475.
59. Solayman MH, Langae TY, **Gong Y**, Shahin MH, Turner ST, Chapman AB, Gums JJ, Boerwinkle E, Beitelshes AL, El-Hamamsy M, El-Wakeel L, Cooper-DeHoff RM, Badary OA, Johnson JA. Effect of Plasma MicroRNA on the Antihypertensive Response to beta-blocker in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Studies. *Eur J Pharm Sci.* 2019 Apr 1;131:93-98. doi: 10.1016/j.ejps.2019.02.013. Epub 2019 Feb 10. PubMed PMID: 30753892.
60. Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, **Gong Y**, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lytykäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardiissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A,

- Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J, Van der Harst P, Tardif JC, Sattar N, Lang CC, Paré G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW. Association of Chromosome 9p21 with Subsequent Coronary Heart Disease events: A GENIUS-CHD study of individual participant data. *Circ Genom Precis Med.* 2019 Mar 21. doi: 10.1161/CIRCGEN.119.002471. [Epub ahead of print] PubMed PMID: 30897348.
61. Patel R, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, **Gong Y**, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lytykäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engström T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardiissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots M, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczechlik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Paré G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW. Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. *Circ Genom Precis Med.* 2019 Mar 21. doi: 10.1161/CIRCGEN.119.002470. [Epub ahead of print] PubMed PMID: 30896328.
62. Yang X, Bian J, **Gong Y**, Hogan WR, Wu Y. MADEx: A system for Detecting Medications, Adverse Drug Events and their Relations from Clinical Notes. *Drug Saf.* 2019 Jan 2. doi: 10.1007/s40264-018-0761-0. [Epub ahead of print] PubMed PMID: 30600484.
63. Smith SM, Gurka MJ, **Gong Y**, Handberg E, Pepine CJ, Cooper-DeHoff RM. Intensive versus Standard Systolic Blood Pressure Targets in Treatment-resistant Hypertension: A pooled Analysis of SPRINT and ACCORD-DBP Data. *Am J Med.* 2018 Dec;131(12):1463-1472.e7. doi: 10.1016/j.amjmed.2018.08.005. Epub 2018 Aug 22. PubMed PMID: 30142317; PubMed Central PMCID: PMC6279479.

64. Magvanjav O, Cooper-DeHoff RM, McDonough CW, **Gong Y**, Segal MS, Hogan WR, Johnson JA. Antihypertensive Therapy Prescribing Patterns and Correlates of Blood Pressure Control among Hypertensive Patients with Chronic Kidney Disease. *J Clin Hypertens (Greenwich)*. 2018 Nov 14. doi: 10.1111/jch.13429. [Epub ahead of print] PubMed PMID: 30427124.
65. Cicali EJ, Blake K, **Gong Y**, Mougey EB, Al-Atrash H, Chambers N, Denham J, Evans J, George DE, Gomez R, Palomo P, Taufiq S, Johnson JA, Lima JJ, Franciosi JP. Novel implementation of genotype-guided proton pump inhibitor medication therapy in children: a pilot, randomized, multi-site pragmatic trial. *Clin Transl Sci*. 2018 Oct 20. doi: 10.1111/cts.12589. [Epub ahead of print] PubMed PMID: 30341969.
66. Singh S, Wang Z, Shahin M, Langae TY, **Gong Y**, Turner ST, Chapman AB, Gums JG, McDonough CW, Bailey KR, Beitelshes AL, Cooper-DeHoff RM, Scherer S, Boerwinkle B, Johnson JA. Targeted Sequencing Identifies Missense Variant in the *BEST3* Gene Associated with Antihypertensive response to Hydrochlorothiazide. *Pharmacogenet Genomics*. 2018 Nov;28(11):251-255. doi: 10.1097/FPC.0000000000000353. PubMed PMID: 30289819.
67. Wazzan T, Kashtwari D, Almaden WF, **Gong Y**, Chen Y, Moreb J, Katz J. Radiographic Bone Loss and the Risk of Medication Related Osteonecrosis of the Jaw (MRONJ) in Multiple Myeloma Patients. *Spec Care Dentist*. 2018 Sep 8. doi: 10.1111/scd.12318. [Epub ahead of print] PubMed PMID: 30194738.
68. Kawaguchi-Suzuki M, Cusi, Bril F, **Gong Y**, Langae TY, Frye RF. A Genetic Response Score for Pioglitazone Use in Patients with Nonalcoholic Steatohepatitis. *Front Pharmacol*, 2018;9(752). doi:[10.3389/fphar.2018.00752](https://doi.org/10.3389/fphar.2018.00752). eCollection 2018. PubMed PMID: 30065651; PubMed Central PMCID: PMC6056641.
69. Sa ACC, Webb A, **Gong Y**, McDonough CW, Shahin MH, Datta S, Langae TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Blood pressure Signature Genes and Blood Pressure Response to Thiazide Diuretics: Results from the PEAR and PEAR-2 Studies. *BMC Medical Genomics*, 2018 Jun 20;11(1):55. doi: 10.1186/s12920-018-0370-x. PubMed PMID: 29925376
70. Mosley S, Hick JK, Donovan K, Gopalan P, Schmit J, Starr J, Silver N, Portman DG, **Gong Y**, Langae TY, Clare-Salzler M, Starostik P, George TJ, McLeod H, Cavallari LH. Design and Rational for the Precision Medicine Guided Treatment for Cancer Pain Pragmatic Clinical Trial. *Contemp Clin Trials*. 2018 May;68:7-13. doi: 10.1016/j.cct.2018.03.001. Epub 2018 Mar 10. PubMed PMID: 29535047; PubMed Central PMCID: PMC5899651.
71. Cavallari LH, Franchi F, Rollini F, Been L, Rivas A, Agarwal M, Smith DM, Newsome K, **Gong Y**, Elsey AR, Starostik P, Johnson JA, Angiolillo D. Clinical Implementation of Rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. *J Transl Med*. 2018 Apr 11;16(1):92. doi: 10.1186/s12967-018-1469-8. PubMed PMID: 29642909.
72. McDonough CW, Magvanjav O, Sa ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh R, Solayman M, Bailey KR, Boerwinkle E, Chapman AB,

- Gums JJ, Turner ST, Cooper-DeHoff RM, **Gong Y**, Johnson JA. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients from the Pharmacogenomics Evaluation of Antihypertensive Responses (PEAR) Study. *Circ Genom Precis Med.* 2018 Apr;11(4):e001854. doi: 10.1161/CIRCGEN.117.001854. PubMed PMID: 29650764.
73. Shah C, **Gong Y**, Szady A, Sun Qian, Pepine CJ, Langae TY, Lucas AR, Moreb JS. Unanticipated cardiotoxicity due to targeted anticancer therapy in patients with hematologic malignancies: National history and risk factors. *Cardiovasc Toxicol.* 2018 Apr;18(2):184-191. doi: 10.1007/s12012-017-9429-8. PMID: 29022233.
74. Yu G, Wu D, **Gong Y**, Li G, Zhou HH. Conflicting meal recommendations for oral oncology drugs: pose risks to patient care? *Eur J Clin Pharmacol.* 2018 Jun;74(6):833-842. doi: 10.1007/s00228-018-2439-z. Epub 2018 Mar 13. PubMed PMID: 29536134.
75. **Gong Y**, Smith SM, Handberg EM, Pepine CJ, Cooper-DeHoff RM. Intensive Blood Pressure Lowering Reduces Adverse Cardiovascular Outcomes among Patients with high-normal glucose: an analysis of the Systolic Blood Pressure Intervention Trial database. *J Clin Hypertens (Greenwich)*. 2018 Mar 13. doi: 10.1111/jch.13247. [Epub ahead of print] PubMed PMID: 29532983.
76. Singh S., McDonough C.W., **Gong Y**, Alghamdi W., Arwood M.J., Bargal S.A., Dumeny L., Wen-Yi L., Mehanna M., Stockard B., Yang G., de Oliveira F., Fredette N.C., Shahin M.H., Bailey K.R., Beitelshes A.L., Boerwinkle E., Chapman A.B., Gums J.G., Turner S.T., Cooper-DeHoff R.M., Johnson J.A. Genome wide association study identifies the *HMGCS2* locus to be associated with chlorthalidone induced glucose increase in hypertensive patients. *J Am Heart Assoc.*, 2018 Mar 9;7(6). pii: e007339. doi: 10.1161/JAHA.117.007339. PMID: 29523524
77. Shahin MH, Conrado DJ, Gonzalez D, **Gong Y**, Lohmeyer M, Cooper-DeHoff RM, Boerwinkle E, Turner ST, Chapman AB, Gums JG, Johnson JA. Genome-wide Association Approach identified novel genetic predictors of Heart Rate Response to β-blockers. *J Am Heart Assoc.*, 2018 Feb 24;7(5). pii: e006463. doi: 10.1161/JAHA.117.006463. PMID: 29478026
78. Yang G, Hamadeh IS, Katz J, Riva A, Lakatos P, Bernadett B, Kosa J, Vaszikko M, Pelliccioni GA, Davis N, Langae TY, Moreb JS, **Gong Y**. *SIRT1/HERC4* Locus Associated with Bisphosphonate-induced Osteonecrosis of the Jaw: An Exome-wide Association Analysis. *J Bone Miner Res.*, 2018 Jan;33(1):91-98. doi: 10.1002/jbmr.3285. PubMed PMID: 28856724.
79. Weitzel K, Smith DM, Elsey AR, Duong BQ, Burkely B, Clare-Salzler M, **Gong Y**, Higgins TA, Kong B, Langae TY, McDonough CW, Staley BJ, Vo TT, Wake DT, Cavallari LH, Johnson JA. Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. *Clin Transl Sci.* 2018 Mar;11(2):175-181. doi: 10.1111/cts.12533. PubMed PMID: 29351371.

80. Cavallari LH, Lee CR, Beitelshees AL, Duarte JD, Voora D, Kimmel SE, Cooper-DeHoff RM, McDonough CW, **Gong Y**, Dave CD, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh I, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJ, Keleman MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba D, Rakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake D, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA, on behalf of the IGNITE Network Pharmacogenetics Working Group. Multi-site Investigation of Outcomes with Implementation of CYP2C19-Genotype guided antiplatelet therapy after Percutaneous Coronary Intervention. *JACC Cardiovasc Interv* 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1. PubMed PMID: 29102571; PubMed Central PMCID: PMC5775044.
81. Shahin M, **Gong Y**, Frye R, Rotroff D, Beitelshees AL, Baillie R, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA. Spingomyeline Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights from Genomics, Metabolomics, and Lipidomics. *J Am Heart Assoc.* 2017 Dec 29; 7(1): pii:e006656. PMID: 29288159
82. Huo T, Canepa R, Sura A, Modave F, **Gong Y**. Colorectal Cancer Stages Transcriptome Analysis. *PLoS One*. 2017 Nov 28;12(11):e0188697. doi: 10.1371/journal.pone.0188697. eCollection 2017. PubMed PMID: 29182684.
83. Sa ACC, Webb A, **Gong Y**, McDonough CW, Datta S, Langae TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. *Scientific reports*. 2017; 7(1):16068. PMID: 29167564.
84. Li G, Yu G, **Gong Y**. Proton Pump Inhibitors and Capecitabine Efficacy: Time-independent or Time-dependent Effect? *JAMA Oncol*. 2017 Nov 2. doi: 10.1001/jamaoncol.2017.3407. [Epub ahead of print] PubMed PMID: 29098270.
85. Magvanjav O, **Gong Y**, McDonough CW, Beitelshees AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. *J Am Heart Assoc*. 2017 Nov 2;6(11). pii: e006522. doi: 10.1161/JAHA.117.006522. PubMed PMID: 29097388.
86. Mehanna M, **Gong Y**, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Johnson JA, Turner ST, Cooper-DeHoff RM. Blood Pressure Responses to Metoprolol and Chlorthalidone in Hypertensive European and African Americans. *J Clin Hypertens (Greenwich)*. 2017 Sep 21. doi: 10.1111/jch.13094. [Epub ahead of print]. PMID: 28940643

87. Wokhlu A, Smith SM, **Gong Y**, Handberg EM, Elgendi IY, Bavry AA, Cooper-DeHoff RM, Pepine CJ. Mortality implications of lower archived diastolic blood pressure with lower achieved systolic pressures in Coronary Artery Disease: Long-term Mortality Results from the U.S. Cohort of INternational VErapamil SR Trandolapril STudy (INVEST). *J Hypertens.* 2017 Sep 21. doi: 10.1097/HJH.0000000000001559. [Epub ahead of print]. PMID: 28938338.
88. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, **Gong Y**, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hoefer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczechlik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS; GENIUS-CHD consortium., Krämer BK, Scharnagl H, Fliser D, März W, Speer T. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol.* 2017 Jul;5(7):534-543. doi: 10.1016/S2213-8587(17)30096-7. Epub 2017 May 26. [Epub ahead of print] PubMed PMID: 28566218.
89. Magvanjav O, McDonough CW, **Gong Y**, McClure LA, Talbert RL, Horenstein RB, Mitchell BD, Shuldiner AR, Benavente OR, Johnson JA. Pharmacogenetic associations of beta-1 adrenergic receptor polymorphisms with cardiovascular outcomes in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. *Stroke.* 2017 May;48(5):1337-1343. pii: STROKEAHA.116.015936. doi: 10.1161/STROKEAHA.116.015936. Epub 2017 Mar 28. PubMed PMID: 28351962; PubMed Central PMCID: PMC5404951.
90. Miller K, Branco-de-Almeida LS, Wolf Sandra, Hovencamp N, Treloar T, Harrison P, Aukhil I, **Gong Y**, Shaddox LM. Long-term Clinical Response to Treatment and Maintenance of Localized Aggressive Periodontitis. *J Clin Periodontol.* 2017 Feb;44(2):158-168. doi: 10.1111/jcpe.12640. PubMed PMID: 27767222; PubMed Central PMCID: PMC5303544.
91. Shahin MH, Sa AC, Webb A, **Gong Y**, Langae TY, McDonough CW, Riva A, Beitelshes AL, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Scherer SE, Sadee W, Cooper-DeHoff RM, and Johnson JA. Genome Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated with Thiazide Diuretics Blood Pressure Response. *Circ Cardiovasc Genet.* 2017 Jan;10(1). pii: e001404. doi:10.1161/CIRGENETICS.116.001404. PubMed PMID: 28115488. PubMed Central PMCID: PMC5298887.
92. Salvi E, Wang Z, Rizzi F, **Gong Y**, McDonough CW, Padmanabhan S, Hiltunen TP, Lanzani C, Zaninello R, Chittani M, Bailey KR, Barcella M, Chapman AB, Johnson JA, Dominiczak AF,

- Kontula KK, Manunta P, Glorioso N, Barlassina C, Cusi D, Boerwinkle R, Cooper-DeHoff RM, Turner ST. Genome-wide and Gene-based Meta-Analyses to identify loci influencing antihypertensive response to hydrochlorothiazide. *Hypertension*. 2017 Jan;69(1):51-59. doi: 10.1161/HYPERTENSIONAHA.116.08267. PubMed PMID: 27802415. PubMed Central PMCID: PMC5145728.
93. Elgendi IY, Bavry AA, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Long-term mortality in a cohort of hypertensive patients with coronary artery disease: Results from the INternational VErapamil/Trandolapril STudy. *Hypertension*. 2016 Nov;68(5):1110-1114. PubMed PMID: 27620390; PubMed Central PMCID: PMC5063713.
94. Smith MS, Huo T, **Gong Y**, Handberg EM, Gulati M, Merz NB, Pepine CJ, Cooper-DeHoff RM. Mortality and Cardiovascular risk associated with apparent treatment-resistant hypertension among women. *J Womens Health (Larchmt)*. 2016 Oct;25(10):996-1003 PubMed PMID: 27224417; PubMed Central PMCID: PMC5069707.
95. Weng L, **Gong Y**, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Beitelshees AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Presence of Arachidonoyl-Carnitine is Associated with Adverse Cardiometabolic Responses in Hypertensive Patients Treated with Atenolol. *Metabolomics* (Los Angel). 2016 Oct;12(10). pii: 160. doi: 10.1007/s11306-016-1098-2. PubMed PMID: 28217401.
96. Chang SW, McDonough CW, **Gong Y**, Johnson TA, Tsunoda T, Gamazon ER, Perera MA, Takahashi, A, Tanaka T, Kubo M, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Genome-wide Association study identified Pharmacogenomic Loci Associated with Antihypertensive Treatment-Related New-Onset Diabetes. *Pharmacogenomics J*. 2016 Sep 27. doi: 10.1038/tpj.2016.67. PMID: 27670767; PubMed Central PMCID: PMC5368017.
97. Shahin MH, **Gong Y**, McDonough CW, Rotroff DM, Beitelshees AL, Garrett T, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Oliver F, Cooper-DeHoff RM, Kaddurah-Daouk R, and Johnson JA. A Genetic Response Score for Hydrochlorothiazide Use: Insights from Genomics and Metabolomics Integration. *Hypertension*, 2016 Sep;68(3):621-9. PMID: 27381900
98. De Oliveria FA, Shahin MH, **Gong Y**, McDonough CW, Beitelshees AL, Gums JJ, Chapman AB, Boewinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Novel Plasma Biomarker of Atenolol-Induced Hyperglycemia identified through a metabolomics-Genomics Integrative Approach. *Metabolomics* (Los Angel). 2016 Aug;12. pii: 129. doi: 10.1007/s11306-016-1076-8. PubMed PMID: 28217400; PubMed Central PMCID: PMC5310671.
99. Zhu HJ, Langaee TY, **Gong Y**, Wang X, Pepine CJ, Cooper-DeHoff RM, Johnson JA, Markowitz JS. No association between the CES1P1 variant -816A>C with hepatic carboxylesterase 1 expression and activity and antihypertensive effect of trandolapril. *Eur J*

- Clin Pharmacol.* 2016 Jun;72(6):681-7. doi: 10.1007/s00228-016-2029-x. Epub 2016 Feb 26. PubMed PMID: 26915813; PubMed Central PMCID: PMC4865408.
100. Hoh BL, **Gong Y**, Waters M, Royster A, Sheehan T, Burkley B, McDonough CW, Mocco J, Zuckerman S, Ingram C, Shaffer CM, Denny J, Brilliant M, Kitchner T, Roden D, Johnson JA. *CYP2C19 and CES1 Polymorphisms and Efficacy of Aspirin and Clopidogrel Dual Antiplatelet Therapy in Patients with Symptomatic Intracranial Atherosclerotic Disease.* *J Neurosurg.* 2016 Jun;124(6):1746-51. doi: 10.3171/2015.6.JNS15795. Epub 2015 Nov 20. PubMed PMID: 26587656; PubMed Central PMCID: PMC4915569.
 101. Chang SW, **Gong Y**, McDonough CW, N. Nasiri Kenari, T. Langaee, A.L. Beitelshes, J.G. Gums, A.B. Chapman, S.T. Turner, J.A. Johnson, Cooper-DeHoff RM. Melatonin Pathway and Atenolol-Related Glucose Dysregulation – Is there a Correlation? *Clin Transl Sci.* 2016 Apr;9(2):114-22. PubMed PMID: 26946962; PubMed Central PMCID: PMC4915567.
 102. **Gong Y**, Wang Z, Beitelshes AL, McDonough CW, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic Genome-wide Meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. *Hypertension.* 2016 Mar;67(3):556-63. PubMed PMID: 26729753; PubMed Central PMCID: PMC4752391.
 103. Khalil BM, Shahin MH, Langaee TY, Shaalan MF, **Gong Y**, Hammad LN, Al-Mesallamy HO, Hamdy NM, El-Hammady WA, Johnson JA. Genetic and Non-genetic factors among clopidogrel efficacy in Egyptian population. *Clin Transl Sci.* 2016 Jan 12. doi: 10.1111/cts.12383. PubMed PMID: 26757134; PubMed Central PMCID: PMC4760893.
 104. Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, Lesko LJ, **Gong Y**. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). *J Bone Miner Res.* 2016 Feb;31(2):336-40. PubMed PMID: 26288087
 105. Prabhakaran S, Kim K, **Gong Y**, Hendeles L. Long Term Variability in Exhaled Nitric Oxide Measurements. *J Allergy Clin Immunol Pract.* 2016 Jan-Feb;4(1):147-148.e1. PMID: 26563669
 106. Rotroff DM, Shahin MH, Gurley S, Zhu H, Motsinger-Reif A, Meisner M, Beitelshes AL, Fiehn O, Johnson JA, El-Badawi M, Frye RF, **Gong Y**, Weng L, Cooper-DeHoff RM, Kaddurah-Daouk RF. Pharmacometabolomic Assessment of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. *CPT Pharmacometrics Syst Pharmacol.* 2015 Nov;4(11):669-79. doi: 10.1002/psp4.12017. Epub 2015 Oct 29. PubMed PMID: 26783503.
 107. **Gong Y**, McDonough CW, Beitelshes AL, Rouby NE, Hiltunen TP, O'Connell JR, Padmanabhan S, Langaee TY, Hall K, Schmidt SO, Curry RW Jr, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Chapman AB, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. *PTPRD gene associated with blood pressure*

- response to atenolol and resistant hypertension. *J Hypertens.* 2015 Nov;33(11):2278-85. PubMed PMID: [26425837](#); PubMed Central PMCID: PMC4788379.
108. Feild C, Belgado B, Dougherty J, Doering P, **Gong Y**. The Use of Application based Learning Techniques in a College of Pharmacy Based Biostatistics Course. *Currents in Pharmacy Teaching and Learning.* 2015;7:599-605
109. Chittani M, Zaniello R, Lanzani C, Frau F, Ortu MF, Slavi E, Fresu G, Citterio L, Braga D, Piras DA, Carpini SD, Velayutham D, Simonini M, Argiolas G, Possoli S, Troffa C, Glorioso V, Knotula K, Hiltunen TP, Donner KM, Turner ST, Boerwinkel E, Chpaman AB, Padmanaghan S, Dominiczak AF, Melander O, Johnson JA, Cooper-DeHoff RM, **Gong Y**, Manunta P, Cusi D, Glorioso N, Barlassina C. TET2 and CSMD1 genes affect systolic blood pressure response to hydrochlorothiazide in never treated essential hypertensives. *J Hypertens.* 2015 Jun;33(6):1301-9. PubMed PMID: 25695618.
110. Weng L, Eoin Q, **Gong Y**, Beitelshes AL, Shahin MH, Turner ST, Chapman AB, Gums JG, Johnson JA, Frye RF, Garrett TJ, Cooper-DeHoff RM. Association of Branched and Aromatic Amino Acids Levels with Metabolic Syndrome and Impaired Fasting glucose in Hypertensive Patients. *Metab Syndr Relat Disord.* 2015 Jun;13(5):195-202. doi: 10.1089/met.2014.0132. Epub 2015 Feb 9. PubMed PMID: 25664967.
111. McDonough CW, McClure LA, Mitchell BD, **Gong Y**, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR. CYP2C19 Metabolizer Status and Clopidogrel Efficacy in The Secondary Prevention of Small Subcortical Strokes (SPS3) Study. *J Am Heart Assoc.* 2015 May 27;4(6). pii: e001652. doi: 10.1161/JAHA.114.001652. PubMed PMID: 26019129.
112. Hamadeh IS, Ngwa BA, **Gong Y**. Drug induced osteonecrosis of the jaw. *Cancer Treat Rev.* 2015; 41 (5), 455-464. PubMed PMID: 25913713.
113. Bavry AA, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Impact of Aspirin According to Type of Ischemic Heart Disease: Insight from a Large International Database. *Am J Med.* 2015 Feb;128(2):137-43. PMID: 25447610
114. Hiltunen TP, Donner K, Sarin A, Saarela J, Ripatti S, Chapman A, Gums JG, **Gong Y**, Cooper-DeHoff RM, Frau F, Glorioso V, Zaninello R, Slavi E, Florioso N, Boerwinkle E, Turner ST, Johnson JA, Kontula K. Pharmacogenomics of Hypertension: A genome-wide placebo-controlled cross-over study, using four classes of antihypertensive drugs. *J Am Heart Assoc.* 2015;4:e001521 doi: 10.1161/JAHA.114.001521
115. Denardo SJ, **Gong Y**, Keltai M, Szirmai LA, Farsang C, Mancia G, Bavry AA, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. *PLoS One.* 2015 Apr 2;10(4):e0122726. PubMed PMID: 25835002

116. Fontana V*, McDonough CW*, **Gong Y**, El Rouby NM, Sá ACC, Taylor KD, Chen Y-D I, Gums JG, Chapman AB, Turner ST, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Large-Scale Gene-centric Analysis Identifies Polymorphisms for Resistant Hypertension. *These authors contributed equally to this work. *J Am Heart Assoc.* 2014 Nov 10;3(6). pii: e001398. PMID: 25385345.
117. Moore MJ*, **Gong Y***, Hou W, Hall K, Schmidt SO, Curry RW, Beitelshes AL, Chapman AB, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, Coop-DeHoff RM, Johnson JA. Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment with Atenolol or Hydrochlorothiazide. *These authors contributed equally to this work. *Pharmacotherapy*. 2014 Nov;34(11):1132-40. PMID: 25202885.
118. Vandell AG, McDonough CW, **Gong Y**, Langaee TY, Lucas AM, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Hydrochlorothiazide-induced Hyperuricemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *J Intern Med.* 2014 Nov;276(5):486-97. PMID: 24612202
119. Bangalore S, **Gong Y**, Cooper-DeHoff RM, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited: Results from the INVEST Study. *JACC*. 2014; 64 (8): 784-93. PMID: 25145522
120. Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Chapman AB, Gums JG, Turner ST, **Gong Y**, Cooper-DeHoff RM, Johnson JA. Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Immediate Release Metoprolol Tartrate. *Clin Pharmacol Ther.* 2014 Aug;96(2):175-81. PMID: 24637943
121. Karnes JH, **Gong Y**, Arwood MJ, Gums JG, Hall K, Limacher MC, Johnson JA, and Cooper-DeHoff RM. Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. *Diabetes Res Clin Pract.* 2014. Jun;104(3):363-9. PMID: 24794890
122. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshes A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, Cooper-Dehoff RM, Gaunt TR, Gieger C, **Gong Y**, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, Monda KL, Onland-Moret NC, Nelson CP, O'Connell JR, Ordovas J, Peter I, Peters A, Shaffer J, Shen H, Smith E, Speilotes L, Thomas F, Thorand B, Verschuren WM, Anand SS, Dominiczak A, Davidson KW, Hegele RA, Heid I, Hofker MH, Huggins GS, Illig T, Johnson JA, Kirkland S; the Look AHEAD Research Group, König W, Langaee TY, McCaffery J, Melander O, Mitchell BD, Munroe P, Murray SS, Papanicolaou G, Redline S, Reilly M, Samani NJ, Schork NJ, van der Schouw YT, Shimbo D, Shuldiner AR, Tobin MD, Wijmenga C, Yusuf S; the GIANT Consortium; the CARe IBC Consortium, Hakonarson H, Lange LA, Demerath EW, Fox CS, North KE, Reiner AP, Keating B, Taylor KC. Gene-centric meta-analyses for central adiposity traits in up to 57,412 individuals of European descent confirm known loci and reveal several novel associations. *Hum Mol Genet.* 2014 May 1;23(9):2498-510. PMID: 24345515.

123. Cooper-DeHoff RM, Hou W, Weng L, Baillie R, Beitelshes AL, **Gong Y**, Shahin MHA, Turner ST, Chapman AB, Gums JG, Boyle S, Zhu H, Wikoff RW, Boerwinkle E, Feine O, Frye R, Kaddurah-Daouk R, Johnson JA. Is a Diabetes-linked Amino Acid Signature Associated with Beta Blocker-induced Impaired Fasting Glucose? *Circ Cardiovasc Genet*. 2014 Apr 1;7(2):199-205. PMID: 24627569.
124. Chapman AB, Cotsonis G, Parekh V, Schwartz GL, **Gong Y**, Bailey KR, Turner ST, Gums JG, Beitelshes AL, Cooper-DeHoff R, Boerwinkle E, Johnson JA. Night Blood Pressure Responses to Atenolol and Hydrochlorothiazide in Black and White Patients with Essential Hypertension. *Am J Hypertens*. 2014 Apr;27(4):546-54. PMID: 23886594
125. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, Smith EN, Johnson T, Holmes MV, Padmanabhan S, Karczewski KJ, Almoguera B, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Gaunt TR, Gho JM, Gieger C, Goel A, **Gong Y**, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Melander O, Nelson CP, Nolte IM, Pankratz N, Price TS, Shaffer J, Shah S, Tomaszewski M, van der Most PJ, Van Iperen EP, Vonk JM, Witkowska K, Wong CO, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Brown M, Burt A, Cooper-Dehoff RM, Connell JM, Cruickshanks KJ, Curtis SP, Davey-Smith G, Delles C, Gansevoort RT, Guo X, Haiqing S, Hastie CE, Hofker MH, Hovingh GK, Kim DS, Kirkland SA, Klein BE, Klein R, Li YR, Maiwald S, Newton-Cheh C, O'Brien ET, Onland-Moret NC, Palmas W, Parsa A, Penninx BW, Pettinger M, Vasan RS, Ranchalis JE, Ridker P, Rose LM, Sever P, Shimbo D, Steele L, Stolk RP, Thorand B, Trip MD, van Duijn CM, Verschuren WM, Wijmenga C, Wyatt S, Young JH, Zwinderman AH, Bezzina CR, Boerwinkle E, Casas JP, Caulfield MJ, Chakravarti A, Chasman DI, Davidson KW, Doevedans PA, Dominiczak AF, Fitzgerald GA, Gums JG, Fornage M, Hakonarson H, Halder I, Hillege HL, Illig T, Jarvik GP, Johnson JA, Kastelein JJ, Koenig W, Kumari M, März W, Murray SS, O'Connell JR, Oldehinkel AJ, Pankow JS, Rader DJ, Redline S, Reilly MP, Schadt EE, Kottke-Marchant K, Snieder H, Snyder M, Stanton AV, Tobin MD, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani NJ, Watkins H, Johnson AD, Reiner AP, Zhu X, de Bakker PI, Levy D, Asselbergs FW, Munroe PB, Keating BJ. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood pressure related loci. *Am J Hum Genet*. 2014 Mar 6;94(3):349-60. PubMed PMID: 24560520.
126. Rosenwasser R, Shah NK, Smith SM, Wen X, **Gong Y**, Gums JG, Nichols WW, Chapman AB, Boerwinkle E, Johnson JA, Epstein B. Baseline Predictors of Central Aortic Blood Pressure: A PEAR Substudy. *J Am Soc Hypertens*. 2014;8(3):152-8. PMID: 24629400
127. Smith SM, **Gong Y**, Handberg EM, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-DeHoff RM. Clinical Outcomes and Predictors of Resistant Hypertension Among Patients with Coronary Artery Disease. *J Hypertens*. 2014 Mar;32(3):635-43. PMID: 24299915.
128. **Gong Y**, McDonough CW, Beitelshes AL, O'Connell JR, Karnes JH, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA, Cooper-DeHoff RM. PROX1 Gene Variant is Associated with Glucose Change after Antihypertensive Treatment. *Pharmacotherapy*. 2014 Feb;34(2):123-30. PMID: 24122840

129. Karnes JH, **Gong Y**, Pacanowski MA, McDonough CW, Arwood M, Langaee TY, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Impact of *TCF7L2* single nucleotide polymorphisms on Hydrochlorothiazide-induced diabetes. *Pharmacogenet Genomics*. 2013 Dec;23(12):697-705. PMID: 24128935.
130. McDonough CW, Gillis NK, Alsultan A, Chang S, Lang JE, Shahin MH, Suzuki-Kawaguchi M, Buford TW, Langaee TY, Gums JG, Chapman AB, Turner ST, Cooper-DeHoff RM, **Gong Y**, Johnson JA. Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *PLoS One*. 2013; 8(10):e76984. PMID: 24116192
131. Bavry AA, Kumbhani DJ, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Simple Integer Risk Score to Determine Prognosis of Patients with Hypertension and Chronic Stable Coronary Disease. *J Am Heart Assoc*. 2013 Aug 15; 2 (4):e000205. PMID: 23948642
132. Turner ST, Boerwinkle E, O'Connell J, Bailey KR, **Gong Y**, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstand B, Manunta P, Kontula K, Dominiczak AF, Cooper-DeHoff RM, Johnson JA. Genomic Association Analyses of Common Variants Influencing Antihypertensive Response to Hydrochlorothiazide. *Hypertension*. 2013 Aug;62(2):391-7. PMID: 23753411.
133. Winchester DE, Cooper-Dehoff RM, **Gong Y**, Handberg EM, Pepine CJ. Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: new data from extended follow-up of the INternational VErapamil/Trandolapril STudy (INVEST). *Clin Cardiol*. Clin Cardiol. 2013 Aug;36(8):442-7. PMID: 23720247.
134. McDonough CW, **Gong Y**, Padmanabhan S, Burkley B, Langaee TY, Melander O, Pepine CJ, Dominiczak AF, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic association of non-synonymous SNPs in *SIGLEC12*, *A1BG*, and the Selectin Region and Cardiovascular Outcomes. *Hypertension*. 2013 Jul;62(1):48-54. PMID: 23690342.
135. Lima JJ, Lang JE, Mougey EB, Blake KB, **Gong Y**, Holbrook J, Wise RW, Teague WG. Association of *CYP2C19* Polymorphisms on Lansoprazole-Associated Respiratory Adverse Effects in Children. *J Pediatr*. 2013 Sep;163(3):686-91. PMID: 23623526
136. Wikoff WR, Frye R, Zhu H, **Gong Y**, Boyle S, Churchill E, Cooper-DeHoff RM, Beitelshees AL, Lane A, Chapman AB, Turner ST, Fiehn O, Johnson JA, Kaddurah-Daouk R. Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment. *PLOS ONE*, 2013; 8(3):e57639. PMID: 23536766.
137. Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, Chapman AB, Gums JG, Bailey K, **Gong Y**, Turner ST, Johnson JA, Boerwinkle E. Genome-wide association analyses suggest *NELL1* influences adverse metabolic Response to HCTZ in African Americans. *Pharmacogenomics J*. 2014 Feb;14(1):35-40. PMID: 23400010.

138. Lewis JP, Ryan K, O'Connell JR, Horenstein RB, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshes AL, Pakzy R, Parsa A, Tantry US, Bliden KP, Post W, Faraday N, Herzog W, **Gong Y**, Pepine CJ, Johnson JA, Gurbel PA, Shuldiner AR. Genetic Variants in Platelet Endothelial Aggregation Receptor -1 (*PEAR1*) is Associated with Platelet Aggregation and Cardiovascular Outcomes. *Circ Cardiovasc Genet*. 2013 Apr;6(2):184-92. [Epub ahead of print] PMID: 23392654.
139. Ganesh S, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Almoguera Castillo B, Barnard J, Baumert J, Chang YPC, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JMIH, Gieger C, **Gong Y**, Isaacs A, Kleber ME, Mateo Leach I, McDonough CW, Meijis MFL, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Mos PG, Van Iperen EPA, van Setten J, Vonk JM, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Boer JMA, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, Cooper-DeHoff RM, Curtis SP, Dreisbach A, Duggan D, Ehret GB, Fabsitz R, Fornage M, Fox E, Furlong CE, Gansevoort RT, Hofker MH, Hovingh GK, Kirkland SA, Kottke-Marchant K, Kutlar A, LaCroix AZ, Langae TY, Li YR, Lin H, Liu K, Maiwald S, Malik R, METASTROKE, Murugesan G, Newton-Cheh C, O'Connell JR, Onland-Moret NC, Ouwehand WH, Palmas W, Penninx BW, Pepine CJ, Pettinger M, Polak J, Ramachandran VS, Ranchalis J, Redline S, Ridker PM, Rose LM, Scharnagl H, Schork NJ, Shimbo D, Shuldiner AR, Srinivasan SR, Stolk RP, Taylor HA, Thorand B, Trip MD, van Duijn CM, Vasan R, Verschuren WM, Wijmenga C, Winkelmann BR, Wyatt S, Young JH, Boehm BO, Caulfield MJ, Chasman DI, Davidson KW, Doevedans PA, FitzGerald GA, Gums JG, Hakonarson H, Hillege HL, Illig T, Jarvik GP, Johnson JA, Kastelein JJP, Koenig W, LifeLines Cohort Study, März W, Mitchell BD, Murray SS, Oldehinkel AJ, Rader DJ, Reilly MP, Reiner AP, Schadt EE, Silverstein RL, Snieder H, Stanton AV, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani N J, Johnson AD, Munroe PB, de Bakker PIW, Zhu X, Levy D, Keating BJ, Asselbergs FA. Loci influencing blood pressure identified using a cardiovascular gene-centric array. *Hum Mol Genet*. 2013 Apr 15;22(8):1663-78. PMID: 23303523
140. McDonough CW, Burbage SE, Duarte JD, **Gong Y**, Langae TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshes AL, Boerwinkle E, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Association of variants in *NEDD4L* with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. *J Hypertens*. 2013 Apr;31(4):698-704. PMID: 23353631.
141. Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, El Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, **Gong Y**, Pepine C, Laxton RC, Whittaker JC, Tang WH, Johnson JA, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA, Reilly MP, Samani NJ, Ye S. Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden: A Collaborative Meta-Analysis. *J Am Coll Cardiol*. 2013 Mar 5;61(9):957-70. PMID: 23352782.

142. Lang JE., Mougey EB, Allayee H, Blake KB, Lockey R, **Gong Y**, Hossain J, Killen K, Lima JJ. Nutrigenetic response to omega-3 fatty acids in obese asthmatics (NOOA): Rationale and methods. *Contemp Clin Trials*. 2013 Mar;34(2):326-35. PMID: 23298524.
143. Le MT, Lobmeyer MT, Campbell M, Cheng J, Wang Z, Turner ST, Chapman AB, Boerwinkle E, Gums JG, **Gong Y**, Johnson RJ, Johnson JA. Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic and hemodynamic phenotypes in hypertensive individuals. *PLoS ONE* 2013. 8(1): e52062. PMID: 23341889
144. Karnes JH, Langaee TY, McDonough CW, Chang S, Ramos M, Catlin JR, Casanova O, **Gong Y**, Pepine CJ, Johnson JA, and Cooper-DeHoff RM. Lack of association of the *HMGA1* IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. *J Transl Med*. 2013. Jan 9;11(1):12. PMID: 23302499
145. Guo Y, Lanktree MB, Taylor KC, Hakonsarson H, Lange LA, Keating BJ; The IBC 50K SNP array BMI Consortium. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. *Hum Mol Genet*. 2013 Jan 1;22(1):184-201. PMID: 23001569.
146. **Gong Y**, McDonough CW, Wang Z, Cooper-DeHoff RM, Langaee TY, Beitelshes AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Circ Cardiovasc Genet*, 2012 Dec 1;5(6):686-91. PMID: 23087401
147. Asselbergs FW, Guo Y, van Iperen EPA, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almoguera Castillo B, Appelman YE, Barnard J, Baumert J, Beitelshes AL, Bhangale TR, Ida Chen YD, Gaunt TR, **Gong Y**, Hopewell JC, Johnson T, Kleber ME, Langaee TY, Li M, Li YR, Liu K, McDonough CW, Meijs MFL, Middelberg RPS, Musunuru K, Nelson CP, O'Connell JR, Padmanabhan S, Pankow JS, Pankratz N, Rafelt S, Rajagopalan R, Romaine SPR, Schork NJ, Shaffer J, Shen H, Smith EN, Tischfield SE, van der Most PJ, van Vliet-Ostaptchouk JV, Verweij N, Volcik KA, Zhang L, Bailey KR, Bailey KM, Bauer F, Boer JMA, Braund PS, Burt A, Burton PR, Buxbaum SG, Chen W, Cooper-DeHoff RM, Cupples LA, deJong JS, Delles C, Duggan D, Fornage M, Furlong CE, Glazer N, Gums JG, Hastie C, Holmes MV, Illig T, Kirkland SA, Kivimaki M, Klein R, Klein BE, Kooperberg C, Kottke-Marchant K, Kumari M, LaCroix AZ, Mallela L, Murugesan G, Ordovas J, Ouwehand WH, Post W, Saxena R, Scharnagl H, Schreiner PJ, Shah T, Shields DC, Shimbo D, Srinivasan SR, Stolk RP, Swerdlow DI, Taylor Jr. HA, Topol EJ, Toskala E, van Pelt JL, van Setten J, Yusuf S, Whittaker JC, Zwinderman AH, LifeLines Cohort Study, Anand SS, Balmforth AJ, Berenson GS, Bezzina CR, Boehm BO, Boerwinkle E, Casas JP, Caulfield MJ, Clarke R, Connell JM, Cruickshanks KJ, Davidson KW, Day INM, de Bakker PIW, Doevendans PA, Dominicak AF, Hall AS, Hartman CA, Hengstenberg C, Hillege HL, Hofker MH, Humphries SE, Jarvik GP, Johnson JA, Kaess BM, Kathiresan S, Koenig W, Lawlor DA, März W, Melander O, Mitchell BD, Montgomery GW, Munroe PB, Murray SS, Newhouse SJ, Onland-Moret NC, Poulter N, Psaty B, Redline S, Rich SS, Rotter JI, Schunkert H, Sever P, Shuldiner AR, Silverstein RL, Stanton A, Thorand B, Trip

- MD, Tsai MY, van der Harst P, Van Der Schoot E, van der Schouw YT, Monique Verschuren WM, Watkins H, Wilde AAM, Wolffenduttel BHR, Whitfield JB, Hovingh HK, Ballantyne CM, Wijmenga C, Reilly MP, Martin NG, Wilson JG, Rader DJ, Samani NJ, Reiner AP, Hegele RA, Kastelein JJP, Hingorani AD, Talmud PJ, Hakonarson H, Elbers HC, Keating BJ, Drenos F. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *Am J Hum Genet.* 2012 Nov 2;91(5):823-38. PMID: 23063622
148. Vandell AG, Lohmeyer MT, Gawronski BT, Langae TY, **Gong Y**, Gums JG, Beitelshes AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 (GRK4) polymorphisms: beta-blocker Pharmacogenetics and treatment related outcomes in hypertension. *Hypertension*, 2012;60(4):957-64. PMID: 22949529
149. Karnes JH, McDonough CW, **Gong Y**, Vo TT, Langae RY, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Del-Aquila JL, Boerwinkle E, Pepine CJ, Turner ST, Johnson JA, Cooper-DeHoff RM. Association of KCNJ1 Variation with Change in Fasting Glucose and New Onset Diabetes during HCTZ Treatment. *Pharmacogenomics J.* 2013;13(5):430-436. PMID: 22907731
150. Shafiu M, Johnson RJ, Turner ST, Langae T, **Gong Y**, Chapman AB, Gums JG, Johnson JA. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with Hypertension. *Kidney Blood Press Res.* 2012 Jun 8;35(6):477-482. PMID: 22688828.
151. Wang D, Sun X, **Gong Y**, Gawronksi B, Langae TY, Shahin MH, Khalifia SI, Johnson JA. CYP2C9 promoter variable number tandem repeat polymorphism (pVNTR) regulates mRNA expression in human livers. *Drug Metab Dispos.* 2012 May;40(5):884-91. PMID: 22289258.
152. Duarte JD, Zineh I, Burkley B, **Gong Y**, Langae TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Beitelshes AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Effect of Genetic Variation in H3K79 Methylation Regulatory Genes on Clinical Blood Pressure and Blood Pressure Response to Hydrochlorothiazide. *J Transl Med.* 2012 Mar 22;10:56. PMID: 22440088
153. Papp AC, Pinsonneault JK, Wang D, Peters B, Klungel O, **Gong Y**, Maitland-van der Zee A, Johnson JA, Kumari M, Hingorani AD, Talmud PJ, Shah S, Humphriesy SE, Sadee W. Cholesterol Ester Transfer Protein (CETP) Polymorphism affects mRNA Splicing, HDL levels and sex-dependent cardiovascular risk, *PLoS One.* 2012;7(3):e31930. Epub 2012 Mar 5. PMID: 22403620
154. Smith SM, **Gong Y**, Turner ST, Cooper-DeHoff RM, Beitelshes AL, Chapman AB, Bailey K, Boerwinkle E, Johnson JA, Gums JG. Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. *Am J Hypertens.* 2012 Mar;25(3):359-65. PMID: 22089105
155. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, **Gong Y**, Gums JG, Langae TY, Beitelshes AL, Cooper-DeHoff RM, Boerwinkle E, Johnson JA. Association of Chromosome

- 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. *Pharmacogenomics Journal*, 2012, Feb 21. [Epub ahead of print] PMID: 22350108.
156. Sibille K, Langaele TY, Burkley B, **Gong Y**, Glover TL, King C, Riley J, Leeuwenburgh C, Staud R, Bradley LA, Fillingim RB. Chronic pain, perceived stress, and cellular aging: An exploratory study. *Molecular Pain*, 2012 Feb 12;8(1):12 [Epub ahead of print] PMID: 22325162
157. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, Cooper-Dehoff RM, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q, Gieger C, Gilhuijs-Pederson LA, Glessner JT, Goel A, **Gong Y**, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger C, Kumari M, Langaele TY, Lawlor DA, Li M, Lobmeyer MT, Maitland-van der Zee AH, Meijis MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Wolffenbuttel BH, Young T, Zafarmand MH, Zmuda JM; the Look AHEAD Research Group; DIAGRAM consortium, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Caulfield M, Dominiczak A, Shields DC, Bhatt D, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevedans PA, Dorn GW 2nd, Farrall M, Fitzgerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, Johnson JA, Klungel OH, Knowler WC, Koenig W, März W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs F, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJ. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. *Am J Hum Genet*, 2012 Apr 6;90(4):753. Feb 8. [Epub ahead of print] PMID: 22325160
158. Bavry AA, Khaliq A, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Harmful effects of Nonsteroidal Anti-Inflammatory Drugs among Patients with Hypertension and Coronary Artery Disease. *Am J Med*. 2011; 124(7):614-20. PMID: 21596367
159. Shroads AL, Langaele TY, Coats BS, Kurtz TL, Bullock JR, Weithorn D, **Gong Y**, Wagner DA, Ostrov DA, Johnson JA, Stacpoole PW. Human Polymorphisms in the Glutathione Transferase Zeta 1/Maleylacetoacetate Isomerase Gene Influence the Toxicokinetics of Dichloroacetate, *J Clin Pharmacol*. 2012 Jun;52(6):837-49. PMID: 21642471
160. Katz J*, **Gong Y***, Salmasinia D, Hou W, Burkley B, Ferreira P, Casanova O, Langaele TY, Moreb JS. Genetic Polymorphisms and Other Risk Factors Associated with Bisphosphonate Induced Osteonecrosis of the Jaw (BONJ). *Int J Oral Maxillofac Surg*, 2011; 40 (6): 605–611. PMID: 21396799 *first authors

161. **Gong Y**, Beitelshees AL, Cooper-DeHoff RM, Lorbmeyer MT, Langaae TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients with Coronary Artery Disease. *Circ Cardiovasc Genet*. 2011; 4:169-178. PMID: 21372283
162. Shahin MH, Khalifa SI, **Gong Y**, Sallam TH, Hammad LN, Shafey ME, Ali SS, Mohamed MEF, Langaae T, Johnson JA. Genetic and Nongenetic Factors Associated with Warfarin Dose Requirements in Egyptian Patients. *Pharmacogenetics and Genomics*, 2011;21(3):130–135. PMID: 21228733
163. Lanktree MB, Guo Y, Murtaza M, Glessner JT, Bailey SD, Onland-Moret NC, Lettre G, Ongen H, Rajagopalan R, Johnson T, Shen H, Nelson CP, Klopp N, Baumert J, Padmanabhan S, Pankratz N, Pankow JS, Shah S, Taylor K, Barnard J, Peters BJ, M Maloney C, Lorbmeyer MT, Stanton A, Zafarmand MH, Romaine SP, Mehta A, van Iperen EP, **Gong Y**, Price TS, Smith EN, Kim CE, Li YR, Asselbergs FW, Atwood LD, Bailey KM, Bhatt D, Bauer F, Behr ER, Bhangale T, Boer JM, Boehm BO, Bradfield JP, Brown M, Braund PS, Burton PR, Carty C, Chandrupatla HR, Chen W, Connell J, Dalgeorgou C, Boer AD, Drenos F, Elbers CC, Fang JC, Fox CS, Frackelton EC, Fuchs B, Furlong CE, Gibson Q, Gieger C, Goel A, Grobbee DE, Hastie C, Howard PJ, Huang GH, Johnson WC, Li Q, Kleber ME, Klein BE, Klein R, Kooperberg C, Ky B, Lacroix A, Lanken P, Lathrop M, Li M, Marshall V, Melander O, Mentch FD, J Meyer N, Monda KL, Montpetit A, Murugesan G, Nakayama K, Nondahl D, Onipinla A, Rafelt S, Newhouse SJ, Otieno FG, Patel SR, Putt ME, Rodriguez S, Safa RN, Sawyer DB, Schreiner PJ, Simpson C, Sivapalaratnam S, Srinivasan SR, Suver C, Swergold G, Sweitzer NK, Thomas KA, Thorand B, Timpson NJ, Tischfield S, Tobin M, Tomaszweski M, Verschuren WM, Wallace C, Winkelmann B, Zhang H, Zheng D, Zhang L, Zmuda JM, Clarke R, Balmforth AJ, Danesh J, Day IN, Schork NJ, de Bakker PI, Delles C, Duggan D, Hingorani AD, Hirschhorn JN, Hofker MH, Humphries SE, Kivimaki M, Lawlor DA, Kottke-Marchant K, Mega JL, Mitchell BD, Morrow DA, Palmen J, Redline S, Shields DC, Shuldiner AR, Sleiman PM, Smith GD, Farrall M, Jamshidi Y, Christiani DC, Casas JP, Hall AS, Doevendans PA, D Christie J, Berenson GS, Murray SS, Illig T, Dorn GW 2nd, Cappola TP, Boerwinkle E, Sever P, Rader DJ, Reilly MP, Caulfield M, Talmud PJ, Topol E, Engert JC, Wang K, Dominiczak A, Hamsten A, Curtis SP, Silverstein RL, Lange LA, Sabatine MS, Trip M, Saleheen D, Peden JF, Cruickshanks KJ, März W, O'Connell JR, Klungel OH, Wijmenga C, Maitland-van der Zee AH, Schadt EE, Johnson JA, Jarvik GP, Papanicolaou GJ; Hugh Watkins on behalf of PROCARDIS, Grant SF, Munroe PB, North KE, Samani NJ, Koenig W, Gaunt TR, Anand SS, van der Schouw YT; Meena Kumari on behalf of the Whitehall II Study the WHII 50K Group, Soranzo N, Fitzgerald GA, Reiner A, Hegele RA, Hakonarson H, Keating BJ. Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. *Am J Hum Genet*, 2011;88(1):6-18 PMID: 21194676
164. Beitelshees AL, Johnson JA, Hames M, **Gong Y**, Cooper-DeHoff RM, Wu Ju, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase Gene Polymorphism are Associated with Survival among Patients with Cardiovascular Disease in a Sex-dependent Manner. *PLoS ONE* 2010;5(12): e15180 PMID: 21170323

165. Niu Y*, **Gong Y***, Langae TY, Davis H, Elewa H, Beitelshes AL, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Genetic Variation in the Beta 2 Subunit of the Voltage-Gated Calcium Channel (*CACNB2*) and Pharmacogenetic Association with Adverse Cardiovascular Outcomes in the International Verapamil SR- Trandolapril Study-Genetic Substudy (INVEST-GENES) *Circ Cardiovasc Genet*, 2010;3:548-555 PMID: 21156931 *first authors.
166. Denardo SJ, **Gong Y**, Nichols WW, Messerli FH, Cooper-DeHoff RM, Handberg EM, Champion A, Pepine CJ. Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INternational VErapamil SR-Trandolapril STudy (INVEST) Substudy, *American Journal of Medicine* 2010;123:719-726 PMID: 20670726
167. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, Cooper-DeHoff RM, Handberg EM, **Gong Y**, Champion A, Zhao Q, Pepine CJ. Coronary Revascularization Strategy and Outcomes According to Blood Pressure: An INternational VErapamil SR-Trandolapril STudy (INVEST) Substudy. *Am J Cardiol* 2010;106:498-503 PMID: 20691307
168. Cooper-DeHoff RM, **Gong Y**, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight Blood Pressure Control and Cardiovascular Outcomes among Hypertensive Patients with Diabetes and Coronary Artery Disease. *JAMA* 2010;304:61-68 PMID: 20606150
169. Cooper-DeHoff RM, Wen S, Beitelshes AL, Zineh I, Gums JG, Turner ST, **Gong Y**, Hall K, Parekh V, Chapman A, Boerwinkle E, Johnson JA. Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated with Antihypertensive Medications. *Hypertension* 2010;55:61-68 PMID: 19917874
170. Bavry AA, Anderson RD, **Gong Y**, Denardo SJ, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Prognosis and Treatment Considerations of Concomitant Peripheral Arterial and Coronary Artery Disease: Findings from the INVEST Trial. *Hypertension* 2010;55:48-53 PMID: 19996066
171. Beitelshes AL, **Gong Y**, Bailey KR, Turner ST, Chapman AB, Schwartz GL, Gums JG, Boerwinkle E, Johnson JA. Comparison of Office, Ambulatory, and Home Blood Pressure Antihypertensive Response to Atenolol and Hydrochlorothiazide. *J Clin Hypertens* 2010 Jan;12(1):14-21 PMID: 20047624
172. Smith SM, Anderson SD, Wen S, **Gong Y**, Turner ST, Cooper-DeHoff RM, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Thiazide-Induced Hyperglycemia is not Related to Hypokalemia: Results from the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) Study. *Pharmacotherapy* 2009 Oct;29(10):1157-65 PMID: 19792989
173. **Gong Y**, Handberg EM, Copper-DeHoff RM, Matyas K, Johnson JA, Pepine CJ, for the INVEST investigators. Systolic Blood Pressure and Subjective Well-being in Patients with Coronary Artery Disease. *Clin Cardiol* 2009 Nov;32(11):627-32 PMID: 19711440
174. Beitelshes AL, Navare H, Wang D, **Gong Y**, Wessel J, Moss JI, Langae TY, Cooper DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA. CACNA1C Gene Polymorphisms,

- Cardiovascular Disease Outcomes and Treatment Response. *Circ Cardiovasc Genet* 2009 Aug;2(4):362-70 PMID: 20031608.
175. Johnson JA, **Gong Y**, Bailey KR, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshes AL, Boerwinkle E, Gums JG. Combination Antihypertensive Therapy with Hydrochlorothiazide and Atenolol: Effect of Initiation Order. *Clin Pharmacol Ther* 2009 Nov;86(5):533-9 PMID: 19571804
176. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey KR, Cooper-DeHoff RM, Gums JG, Curry RW, **Gong Y**, Beitelshes AL, Schwartz GL, Turner ST. Pharmacogenomics of Antihypertensive Drugs: Rationale and Design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Am Heart J* 2009 Mar;157(3):442-9 PMID: 19249413
177. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, Cooper-DeHoff RM, Handberg EM, **Gong Y**, Champion A, Zhou Q, Pepine CJ. Characteristics and Outcomes of Revascularized Patients with Hypertension: A Substudy of the International Verapamil SR-Trandolapril STudy, *Hypertension* 2009 Apr;53(4):624-30 PMID: 19237684
178. Johnson AD, **Gong Y**, Wang D, Langae TY, Shin J, Cooper-DeHoff RM, Schork NJ, Binkley P, Pepine CJ, Johnson JA, Sadee W. Promoter Polymorphisms in ACE (Angiotension-Converting Enzyme) Associated with Clinical Outcomes in Hypertension. *Clin Pharmacol Ther* 2009 Jan;85(1):36-44 PMID: 18946466
179. Pacanowski MA, **Gong Y**, Cooper-DeHoff RM, Schork NJ, Shriver MD, Langae TY, Pepine CJ, Johnson JA. β -adrenergic Receptor Gene Polymorphisms and β -blocker Treatment Outcomes in Hypertension, *Clin Pharmacol Ther* 2008 Dec;84(6):715-21 PMID: 18615004
180. Gerhard T, **Gong Y**, Beitelshes AL, Lohmeyer MT, Cooper-DeHoff RM, Langae TY, Schork NJ, Pepine CJ, Johnson JA, for the INVEST Investigators. Association between Cardiovascular Outcomes, Diuretic Therapy and the α -adducin Polymorphism: Results from the INternational VErapamil SR-Trandolapril STudy GENetic Substudy (INVEST-GENES). *Am Heart J* 2008 Aug;156 (2):397-404 PMID: 18657677
181. Hassan M, York KM, Li H, Li Q, **Gong Y**, Langae TY, Fillingim RB, Johnson JA, Sheps DS. Association of Beta1-Adrenergic Receptor Genetic Polymorphism with Mental Stress-induced Myocardial Ischemia in Patients with Coronary Artery Disease. *Arch Intern Med* 2008 Apr;168(7):763-70 PMID: 18413560
182. Shin J, Kline S, Moore M, **Gong Y**, Bhanderi V, Schmalfuss CM, Johnson JA, Schofield RS. Association of Diurnal Blood Pressure Pattern with Risk of Hospitalization or Death in Men with Heart Failure. *J Card Fail* 2007;13:656-62 PMID: 17923358
183. Beitelshes AL, **Gong Y**, Wang D, Schork NJ, Cooper-DeHoff RM, Langae TY, Shriner MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA. *KCNMB1* Genotype Influences Response to

- Verapamil SR and Adverse Outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). *Pharmacogenet Genomics* 2007 Sep;17(9):719-729 PMID: 17700361
184. Brunner M, Cooper-Dehoff RM, **Gong Y**, Karnes JH, Langaee TY, Pepine CJ, Johnson JA. Factors Influencing Blood Pressure Response to Trandolapril Add-on therapy in Patients Taking Verapamil SR (from the INternational VErapamil SR Trandolapril STudy (INVEST)). *Am J Cardiol* 2007;99:1549-1554 PMID: 17531579
185. Langaee TY, **Gong Y**, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil. *Clin Pharmacol Ther* 2007;81:386-391 PMID: 17339868
186. Lobmeyer MT, **Gong Y**, Terra SG, Beitelshes AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Patterson HJ, Adams KF, Hill JA, Aranda JM, Johnson JA. Synergistic Polymorphisms of Beta1 and Alpha2c-Adrenergic Receptors and the Influence on Left Ventricular Ejection Fraction Response to Beta-blocker Therapy in Heart Failure. *Pharmacogenet Genomics* 2007;17:277-282 PMID: 17496726
187. Shin J, Lobmeyer MT, **Gong Y**, Zineh I, Langaee TY, Yarandi H, Schofield RS, Aranda JM, Hill JA, Pauly DF, Johnson JA. Relation of Beta (2)-adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients with Heart Failure. *Am J Cardiol* 2007;99:250-255 PMID: 17223428
188. **Gong Y**, Beitelshes AL, Wessel J, Langaee TY, Schork NJ, Johnson JA. Single Nucleotide Polymorphism Discovery and Haplotype Analysis of Ca²⁺-dependent K⁺ Channel Beta-1 Subunit. *Pharmacogenet Genomics* 2007;17:267-275 PMID: 17496725
189. **Gong Y**, Meyer EM, Meyers CA, Klein RL, King MA, Hughes JA. Memory-related Deficits Following Selective Hippocampal Expression of Swedish Mutation Amyloid Precursor Protein in the Rat. *Exp Neurol* 2006; 200:371-377 PMID: 16780838
190. Zuo J, Jian J, Chen SH, Vergara S, **Gong Y**, Xue J, Huang H, Kaku M, Holliday LS. Actin Binding Activity of Subunit B of Vacuolar H⁺-ATPase is Involved in its Targeting to Ruffled Membranes of Osteoclasts. *J Bone Miner Res* 2006;21 (5):714-21 PMID: 16734386
191. **Gong Y**, Wang Z, Liu T, Zhao W, Zhu Y, Johnson JA, Wu R. A Statistical Model for Functional Mapping of Quantitative Trait Loci Regulating Drug Response. *Pharmacogenomics J* 2004;4:315-321 PMID: 15263889
192. **Gong Y**, Chen SZ, Sonntag CF, Sumners C, Klein RL, King MA, Hughes JA, Meyer EM. Recombinant Adeno-associated Virus Serotype 2 Effectively Transduces Primary Rat Brain Astrocytes and Microglia. *Brain Research Protocols* 2004;14:18-24 PMID: 15519948
193. Klein RL, Hamby ME, **Gong Y**, Hirko AC, Wang S, Hughes JA, King MA, Meyer EM. Dose and Promoter Effects of Adeno-associated Viral Vector for Green Fluorescent Protein Expression in the Rat Brain. *Exp Neurol* 2002;176:66-74 PMID: 12093083

LETTERS TO THE EDITOR:

1. **Gong Y**, Beitelshes AL, Cooper-DeHoff RM, Lobmeyer MT, Langae T, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Response to Letter Regarding Article "Chromosome 9p21 Haplotypes and Prognosis in white and Black Patients with Coronary Artery Disease". *Circ Cardiovasc Genet*. 2011;4 (4): e12. PMID: 21846865
2. Cooper-DeHoff RM, **Gong Y**, Pepine CJ. Hypertension Control and Cardiovascular Outcomes among Patients with Diabetes and Coronary Artery Disease Reply. *JAMA* 2010;304:1672-1673

PUBLISHED ABSTRACTS:

1. Alshammari RA, Tantawy M, Castro-Hall E, Abreu M, Villa Alessandro, Yang G, Katz J, Holliday LS, **Gong Y**. A genome-wide DNA methylation analysis reveals different methylation patterns and mechanistic clues of medication-related osteonecrosis of the jaw. *Clin Pharmacol Ther*. 2024. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2024 (Presidential Trainee Award).
2. Bae J, Tantawy M, **Gong Y**, Langae T, Lartey M, Ganu Y, Tachi K, Ojewale O, Obo-Akwa A, Boamah I, Kiser J, Bushman L, Ellison L, Yang H, Anderson PL, Kwara A. Pharmacogenetics of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations and Hepatitis B Virus Suppression During Antiretroviral Therapy in Patients with HIV/HBV coinfection. Presented as a poster (PB2187) in the Pharmacogenomics Poster Session II at the 73rd Meeting of the American Society of Human Genetics (ASHG), November 3, 2023.
3. Tantawy M, Langae T, Wang D, Rubinstein SM, Cornell RF, Lenihan D, Fradley MG, **Gong Y**. MiRNA-125A association with carfilzomib-related cardiovascular adverse events in multiple myeloma patients: prospective observation of cardiac safety with proteasome inhibitor (PROTECT). *Clin Pharmacol Ther*. 2023 (113): S1: PII-049. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2023 Meeting (Travel award) on March 22-24, 2023. <https://doi.org/10.1002/cpt.2835>
4. Shabnaz S, Williams R, Tantawy M, Rubinstein SM, Fradley MG, Baz R, Pepine CJ, Lenihan D, Cornell RF, **Gong Y**. Proteomic Analysis of Carfilzomib Related Heart Failure in Multiple Myeloma Patients from Prospective Study of Cardiac events during Proteasome Inhibitor therapy (PROTECT) Study. *Clin Pharmacol Ther*. 2023 (113): S11: PII-052. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2023 Meeting on March 22-24, 2023. <https://doi.org/10.1002/cpt.2835>
5. Mehanna M, **Gong Y**, McDonough CW, Smith S, Gums J, Chapman AB, Johnson JA, McIntyre L, Cooper-DeHoff RM. Integrated metabolomics analysis reveals mechanistic insights into the ancestral differences in plasma renin activity among patients with hypertension and thiazide diuretics blood pressure lowering effects. *Clin Pharmacol Ther*. 2023 (113): S1: EP-002. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2023 Meeting on March 22-24, 2023. <https://doi.org/10.1002/cpt.2835>

6. Thomas CD, Franchi F, Keeley E, Rossi J, Anderson RD, **Gong Y**, Kerensky RA, McDonough C, Nguyen A, Winget M, Duarte J, Beitelshes A, Johnson JA, Stougger GA, Winterstein A, Angiolillo DJ, Lee CR, Cavallari L. Impact of the ABCD-GENE Score on P2Y12 Inhibitor clinical effectiveness after PCI: A multi-site, real-world investigation. *J Am Coll Cardiol*, 2023, March 7, 81 (8_Supplement): 786-786. Moderated Poster presented at ACC 2023 in New Orleans, LA on March 6, 2023.
7. Huang Y, **Gong Y**, Cavallari LH, Duarte JD. Global proteomic analyses indentified proteins associated with metabolic dysregulation in heart failure patients. Abstract presented at the American College of Clinical Pharmacy (ACCP) Global Conference in Oct 15-18, 2022 in San Francisco.
8. Mehanna M, **Gong Y**, McDonough CW, Gums J, Chapman AB, Johnson JA, McIntyre L, Cooper-DeHoff RM. Metabolomic differences associated with genetic west African Ancestry among Hypertensive patients. *Clin Pharmacol Ther*. 2022 (111): S36: P-117. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Virtual.
9. Thomas CD, Yang G, Elbalkiny S, Huang Y, Nahid NA, Nguyen N, Meanna M, Boerwinkle E, Chapman AB, Gums JG, **Gong Y**, Johnson JA, Cooper-DeHoff RM, McDonough C. Genetic association of uric acid change after thiazide/thiazide-like diuretic treatment-analysis fo the pharmacogenomic evaluation of antihypertensive responses (PEAR) studies. *Clin Pharmacol Ther*. 2022 (111): S52: P-178. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Virtual.
10. Chekka L, **Gong Y**, Nguyen N, Nahid N, Boerwinkle E, Chapman A, Gums J, Cooper-DeHoff, Johnson JA, McDonough C. Novel Genomic Markers of Blood Pressure Response to Thiazide Diuretics in Hypertensive African Americans: Findings using the latest Topmed Imputation Panel. *Clin Pharmacol Ther*. 2022 (111): S71: PW-010. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Virtual Meeting.
11. Tantawy M, Guang Y, Algubelli RR, Rubinstein SM, Fradley MG, Lu Q, Lenihan D, Cornell RF, Baz RC, **Gong Y**. TMSB10/TRABD2A Locus associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: a whole-exome sequencing analysis. *Clin Pharmacol Ther*. 2022 (111): S69: PW-004. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Virtual Meeting (Top abstract award).
12. Nahid N, **Gong Y**, Ngyuen N, Chekk L, Boerwinkle E, Chapman AB, Gums J, Johnson JA, Cooper-DeHoff RM, McDouugh C. Pharmacogenomic genome-wide meta-analysis to identify variants associated with thaizde and thiazide-like diuretic induced glucose change. *Clin Pharmacol Ther*. *Clin Pharmacol Ther*. 2022 (111): S64: PT-008. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Virtual Meeting (Presidential Trainee Award).
13. Nguyen TN, Tantawy M, Zhou Y, Rubinstein SM, Garrett TJ, Baz RC, Fradley MG, Lu Q, Lenihan D, Cornell RF, **Gong Y**. Risk stratification with pre-treatment metabolite risk score for carfilzomib-related cardiotoxicity in multiple myeloma patients. *Clin Pharmacol Ther*. *Clin Pharmacol Ther*. 2022 (111): S66: PT-014. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Virtual Meeting (Presidential Trainee Award).

14. Thomas CD, Franchi F, Rossi JS, Beitelshes AL, Keeley EC, **Gong Y**, Johnson JA, Anderson RD, Kerensky RA, McDonough MW, Souffer GA, Angiolillo DJ, Lee CR, Cavallari LH. Impact of CYP2C19 genotype on prediction of cardiovascular events with the ABCD-Gene score among patients receiving CYP2C19-guided antiplatelet therapy after PCI. *Clin Pharmacol Ther.* 2022 (111): S68: PT-020. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2022 Virtual Meeting (Presidential Trainee Award).
15. Sylvester-Armstrong K, Tantawy M, Reeder C, Cacho N, Ripp S, Ham T, Langaee T, **Gong Y**, Egerman R. Genetic polymorphisms and preterm neonatal respiratory distress syndrome among women treated with betamethasone, *American Journal of Obstetrics & Gynecology* 2002, 226 (1), S180. DOI:<https://doi.org/10.1016/j.ajog.2021.11.313>
16. Thomas CD, Franchi F, Rossi JS, Beitelshes AL, Keeley EC, **Gong Y**, Johnson JA, Anderson RD, Kerensky RA, McDonough CW, Stouffer GA, Angiolillo DJ, Lee CR, Cavallari LH. Examining cardiovascular outcomes with the ABCD-GENE score among patients receiving CYP2C19-guided antiplatelet therapy after PCI. Virtual poster presentation at PGRN-ASHG 2021 Symposium & Posters. October 18th, 2021.
17. Thomas CD, Beitelshes AL, Franchi F, Shahin MH, Kovar L, **Gong Y**, McDonough MW, Johnson JA, Angiolillo DJ, Cavallari LH. Impact of ABCD-GENE Score on Cardiovascular Outcomes with CYP2C19-guided antiplatelet Therapy after PCI: A multi-site Real-world Investigation. *Clin Pharmacol Ther.* 2021 (109): S27: PT21-014. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting (Presidential Trainee Award).
18. Mehanna M, **Gong Y**, McDonough CW, Gums JG, Chapman AB, Turner ST, Johnson JA, McIntyre L, Cooper-DeHoff RM. Metabolomics Reveals Racial Difference in Blood Pressure Response to Metoprolol. *Clin Pharmacol Ther.* 2021 (109): S27: PT21-002. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting (Presidential Trainee Award).
19. Yang G, Chen Y, Tantawy M, Pruitt E, Pepine CJ, Cooper-DeHoff RM, Qing Lu, **Gong Y**. ACE2 Polymorphisms and COVID-19: An analysis from the UK Biobank. *Clin Pharmacol Ther.* 2021 (109): S27: PT21-015. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting (Presidential Trainee Award).
20. Tantawy M, Yang G, Chen Y, Pruitt E, Langaee TY, Cooper-DeHoff RM, Pepine CJ, Qing Lu, **Gong Y**. Genome-wide Association study of Mortality in COVID-19 Patients in The UK Biobank Data. *Clin Pharmacol Ther.* 2021(109): S60: PII-054. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting.
21. Nahid N, Ciccali E, McDonough C, **Gong Y**, Johnson JA. *Impact of CYP2D6 Inhibitors on Opioid therapy in patients with pain.* *Clin Pharmacol Ther.* 2021(109): S39: PII-037. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 Virtual Meeting.
22. Chen Y, Yang G, Singh S, Langaee TY, Cooper-DeHoff RM, Tantawy M, Pruitt EY, Pepine CJ, Lu Q, **Gong Y**. Three Lipid-related Loci Potentially Associated with SARS-CoV-2 infection in the UK Biobank Participants. Presented as a late-breaking poster at the 70th Virtual Meeting of the American Society of Human Genetics (ASHG), October 27-30, 2020.

23. Tantawy M, Chekka LM, Garrett TJ, Singh S, Shah CP, Fradley MG, Cornel RF, Baz R, DeRemer DL, Yuan L, Langaee T, March K, Pepine CJ, Moreb JS, **Gong Y.** Lactate Dehydrogenase B and pyruvate oxidation associated with carfilzomib-related cardiotoxicity in multiple myeloma patients: a multi-omics study. *Circulation*. 2020;142:A15012. https://doi.org/10.1161/circ.142.suppl_3.15012. Presented as a virtual poster at the American Heart Association's Scientific Sessions 2020 November 13-17.
24. Fradley MG, Nguyen NK, Chen Y, Guha A, Upshaw J, Ky B, **Gong Y.** Cardiovascular Toxicities of Cyclin Dependent Kinase (CDK) 4/6 inhibitors in Metastatic Breast Cancer Patients. *Circulation*. 2020;142:A16720. https://doi.org/10.1161/circ.142.suppl_3.16720. Presented as a virtual moderated poster at the American Heart Association's Scientific Sessions 2020 November 13-17.
25. Nguyen NK, Fradley MG, Chen Y, DeRemer D, Waheed N, Langaee T, Ahamed F, Cooper-DeHoff RM, Pepine CJ, **Gong Y.** Racial/ethnic differences in cardiac surveillance evaluation for cancer patients treated with anthracycline-based chemotherapy: the OneFlorida Clinical Research Consortium. *Circulation*. 2020;142:A16457. Presented as an oral presentation at the American Heart Association's Scientific Sessions 2020 November 13-17.
26. Stolte S, Fang R, Wu Y, Hogan WR, **Gong Y.** Artificial intelligence for characterizing heart failure in cardiac magnetic resonance images. *Circulation*. 2020;142:A15036. https://doi.org/10.1161/circ.142.suppl_3.15036 Presented as a virtual poster at the American Heart Association's Scientific Sessions 2020 November 13-17.
27. Yang G, Singh S, McDonough CW, Van Driest S.L, Hamadeh IS, Katz J, Lakatos P, Balla B, Kosa JP, Pelliccioni GA, Price D, Figg WD, Langaee TY, Moreb JS, **Gong Y.** FDFT1 Locus associated with bisphosphonate-related osteonecrosis of the jaw: an international genome-wide meta-analysis. Presented at the 70th Virtual Meeting of the American Society of Human Genetics, October 27-30, 2020. Virtual Meeting.
28. Stolte SE, Wu Y, **Gong Y.**, Fang R. Heart failure classification and prediction from cardiac magnetic resonance imaging using machine learning. Submitted to the 106th Radiological Society of North America Annual meeting in Chicago, IL. Nov 29-Dec 4, 2020.
29. Tantawy M, Chekka LM, Langaee TY, Garrett T, Fradley MG, Cornell RF, Baz RC, Singh S, Yuan L, Shah CP, Waheed N, Pepine CJ, Moreb JS, **Gong Y.** Differential expressions of miR-17 and complement factor D in carfilzomib-related cardiotoxicity in multiple myeloma patients: results of microRNA array and proteomics integrated analysis. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3694.
30. Pruitt EY, Guang Y, Chen Y, Upchurch GR, Johnson JA, **Gong Y.** ADAMTS8 locus associated with abdominal aortic aneurysms in the UK biobank. *Arterioscler Thromb Vasc Biol*. 2020;40:A379. ePoster presented at the Vascular Discovery: From Genes to Medicine 2020 Scientific Sessions; May 5-7, 2020. Published on line on June 29, 2020 at: https://www.ahajournals.org/doi/10.1161/atvb.40.suppl_1.379
31. Lee CR, Beitelishees AL, Tuteja S, Angiolillo DJ, Limdi NA, Empey PE, Lee JC, Johnson JA, Duarte JD, Skaar TC, Cheng Y, **Gong Y.**, McDonough CW, Dillon C, Franchi F, Kruetz RP, Stouffer GA, Cavallari LH. Impact of the CYP2C19 *17 allele on cardiovascular outcomes

- following implementation of genotype-guided antiplatelet therapy in a real-world setting. *Clin Pharmacol Ther.* 2020;107 (S1): Abstract at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 18-21, 2020; Houston TX.
32. Thomas CD, Elsey AR, Starostik P, **Gong Y**, Deen JT, Pulido LF, Prieto H, Fillingim R, Gray CF, Parvataneni HK, Johnson JA, Cavallari LH. Precise Pain Control: Feasibility and Efficacy of a Preemptive CYP2D6-genotype Guided Post-operative Pain Management Paradigm. *Clin Pharmacol Ther.* 2020;107 (S1): S25: PT-013. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting (Presidential Trainee Award); March 18-19, 2020; Houston TX.
33. Mosley SA, El Rouby N, Kim S, Lingineni K, **Gong Y**, Estores, D, Feng K, Kim H, Kinjo M, Langae T, Li Z, Schmidt S, Johnson JA, Frye R, Binkley P, Schmidt S, Cavallari LH. Randomized, Prospective, Clinical trial comparing extended-release (ER) formulations: Metoprolol Succinate Case study. *Clin Pharmacol Ther.* 2020;107 (S1): S99-S100, PIII-080. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 18-19, 2020; Houston TX.
34. Tantawy M, Singh S, Yang G, Gitzendanner M, Chen Y, Wu Y, Fang R, Hogan WR, **Gong Y**. ZMAT4 and DOCK9 variants associated with heart failure in breast cancer patients in the UK Biobank data. *Clin Pharmacol Ther.* 2020;107 (S1): S26, PT-017. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting (Presidential Trainee-David J Goldstein Trainee Award, Top trainee abstract); March 18-19, 2020; Houston TX.
35. Singh S, Yang G, Gitzendanner M, Chen Y, Tantawy M, Wu Y, Fang R, Hogan WR, **Gong Y**. Phospholipase D Pathway Implicated in Heart Failure in Cancer Patients: Results from the UK Biobank. *Clin Pharmacol Ther.* 2020;107 (S1): S84, PIII-020. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 19, 2020; Houston TX.
36. Yang G, Singh S, Chen Y, **Gong Y**. Phenome-wide Association studies (PheWAS) of *SIRT1* SNP in UK Biobank. *Clin Pharmacol Ther.* 2020;107 (S1):S116, PIII-137. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 19, 2020; Houston TX.
37. Yang G, Singh S, Collins JM, Langae T, McDonough CW, Holliday LS, Wang D, Lamba J, **Gong Y**. *SIRT1* functional SNPs associated with bisphosphonate-related osteonecrosis of the Jaw. *Clin Pharmacol Ther.* 2020;107 (S1): S89, PIII-038. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2020 Annual Meeting; March 19, 2020; Houston TX.
38. Huang Y, Garrett TJ, Yuan L, Fradley MG, Cornell RF, Baz RC, Shah CP, Langae TY, Waheed N, March K, Pepine CJ, Moreb JS, **Gong Y**. Global metabolomic profiling reveals lower lysophospholipid levels in multiple myeloma patients with carfilzomib-related cardiotoxicity. *Circulation.* 2019;140:A9892. Presented as a poster at the American Heart Association's Scientific Sessions 2019 (AHA Genomic and Precision Medicine Travel Grant Winner) in Philadelphia, PA on November 18, 2019.

39. Langaee TY, Asher M, **Gong Y**, Lima ET, Antwi S, Enimil A, Dompreeh A, Yang H, Alghamdi WA, Wiesner L, Peloquin CA, Kwara A. Predicting nevirapine concentrations using pharmacogenetics in Ghanaian HIV-infected children (Abstract/Program #499). Poster presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting, Oct 17, 2019 in Houston TX.
40. Yang G, Singh S, Langaee TY, Lamba J, **Gong Y**. S/RT1 Promoter SNP associated with bisphosphonate-related osteonecrosis of the Jaw. Poster presented at American Society of Bone and Mineral Research (ASBMR) 2019 Annual Meeting (Young Investigator Award), Sep 22, 2019 in Orlando FL.
41. Mehanna M, Chen YE, **Gong Y**, Handberg EM, Roth B, De Leon J, Smith SM, Paulson H, Montilla-Crespo J, Harrell JG, Cooper-DeHoff RM. Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control (OPTI-BP): A Pilot Study Utilizing a Smartphone App. *Hypertension* 2019;74(Supp.1):AP181. Poster presentation at the AHA Annual Meeting. September 5-8, 2019. New Orleans, LA.
42. Waheed N, Mahmoud A, Shah C, Yonghui Wu, March K, Pepine CJ, **Gong Y**. Global longitudinal strain among patients with immune checkpoint inhibitor-induced cardiotoxicity: a case series. *JACC. March 2019* 73 (9 S1):1595; DOI: 10.1016/S0735-1097(19)32201-6 Presented as a poster at the American College of Cardiology's 68th Annual Scientific Session. March 17, 2019 in New Orleans, LA.
43. Thomas CD, Mosley SA, El Rouby N, Kim S, Lingineni K, Langaee T, **Gong Y**, Johnson JA, Schmidt SO, Schmidt S, Frye RF, Cavallari LH. Determination of CYP2D6 Phenotyping for Metoprolol using the CYP2D6 Genotype-derived Activity Score: Results from a Prospective, Clinical Trial. *Clinical Pharmacology & Therapeutics* 2019, 105 (S1):S40: LB-028. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting; March 13, 2019; Washington DC.
44. Shahin MH, **Gong Y**, Singh S, Beitelshes AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Garrett T, Johnson JA. Machine learning uncovers novel biomarkers of antihypertensive response in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Clinical Pharmacology & Therapeutics*. 2019: 105 (S1): S27: PT-013. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting (Presidential Trainee Winner); March 13, 2019; Washington DC.
45. Singh S, Warren HR, Hiltunen TP, Slavi E, El-Rouby N, Garofalidou T, Fyhruist F, Kontula KK, Glorioso V, Zaninello R, Glorioso, Pepine CJ, Munroe PB, Beitelshes AL, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, **Gong Y**, Cooper-DeHoff RM. Genome wide meta-analysis of blood pressure response to B-blockers: Results from International Consortium of Antihypertensive Pharmacogenomics Studies. *Clinical Pharmacology & Therapeutics* 2019, 105 (S1):S27: PT-014. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting (Presidential Trainee Winner); March 13, 2019; Washington DC.
46. Yang G, Singh S, McDonough CW, Hamadeh IS, Langaee TY, Katz J, Lakatos P, Balla B, Kosa JP, Vasziklo M, Pelliccioni GA, Price D, Milshtein KG, Figg WD, Moreb JS, **Gong Y**. An international genome-wide meta-analysis of bisphosphonate related osteonecrosis of the jaw. *Clinical Pharmacology & Therapeutics* 2019, 105 (S1):S28: PT-016. Abstract presented at the

- American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting (Presidential Trainee Winner); March 13, 2019; Washington DC.
47. Lima ET, **Gong Y**, Langaee T, Antwi S, Enimil A, Dompreh A, Kwara A. The effect of CAR and PXR genetic variation (SNPs) on efavirenz pharmacokinetics in Ghanaian HIV+ and HIV/TB+ children. *Clinical Pharmacology & Therapeutics* 2019; 105 (S1):S104: PIII-078. Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2019 Annual Meeting; March 15, 2019; Washington DC.
48. Cooper-Dehoff RM, **Gong Y**, McAuliffe K, Bian J, Song W, Linton MF, Fonseca Price-Haywood, Guhl EN, King JB, Shaw R, PuroJ, Margolis K, Chamberlain A. PCSK9 Inhibitor Use in the Real World: Data from the National Patient Centered Research Network (PCORNet). *Circulation* 2018;138:e751–e782. Presented as a Late-breaking abstract at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
49. Waheed N, Shah C, Boyd C, March K, Moreb JS, Yonghui Wu, **Gong Y**. Cardiotoxicity Associated with Immune Checkpoint Inhibitors: A single Center Experience. *Circulation*. 2018;138:A14262. Presented as a poster at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
50. Shah C, Waheed N, Boyd C, March K, Yonghui Wu, **Gong Y**, Moreb JS. Cardiotoxicity due to Proteasome Inhibitors: More likely With Immunomodulators Or Anthracyclines. *Circulation*. 2018;138:A16441. Presented as a poster at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
51. Shah C, Moreb JS, Kannampuzha J, Yaron J, Ambadapadi S, Yao J, Schultz-Cherry S, House M, Maranian P, Zhang L, **Gong Y**, Pepine CJ, Varsani A, Lucas A. Identification of Viral Gene Signatures in Cancer Patients with Reduced Ejection Fraction After Chemotherapy. *Circulation*. 2018;138:A15398. Presented as a poster at the American Heart Association's Scientific Sessions 2018. Chicago, IL. November 11, 2018.
52. Mosley S, Frye R, Langaee T, Schmidt S.O.F., Schmidt S, **Gong Y**, Binkley P, Johnson JA, Cavallari LH. Determination of CYP2D6 phenotyping for metoprolol using the genotype-derived activity score. Poster presentation for ACCP Updates in Therapeutics 2018 meeting (F-42). Jacksonville, FL. February 16-18, 2018.
53. Smith DM, Weitzel KW, Elsey AR, Wake DT, **Gong Y**, Duong BQ, Newsom K, Smith SM, Starostik P, Clare-Salzler MJ, Schmidt SO, Johnson JA, Fillingim R, Cavallari LH. Outpatient CYP2D6 Genotype -Supported Opioid Therapy: A Prospective Trial. *Clinical Pharmacology & Therapeutics* 2018; 103: S1. (PT-012). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
54. Schwartz EJ, Mougey EB, Chambers NA, Denham JM, Al-Atrash H, Gomez RA, Palomo PJ, Taufiq S, George DE, Evans J, **Gong Y**, Blake KV, Johnson JA, Lima JJ, Franciosi JP. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Therapy in Children: A Pilot, Randomized, Multi-Site Pragmatic Trial. *Clin Pharmacol Ther* 2018;103:S16 (LB-003). Abstract

- presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
55. S. Singh, Z. Wang, M.H. Shahin, T.Y. Langaee, **Y. Gong**, C.W. McDonough, K.R. Bailey, S.T. Turner, A. Chapman, J.G. Gums, A.L. Beitelshes, R.M. Cooper-DeHoff, S. Scherer, E. Boerwinkle, J.A. Johnson. TARGETED SEQUENCING IDENTIFIES MISSENSE VARIANT IN THE BEST3 GENE ASSOCIATED WITH ANTIHYPERTENSIVE RESPONSE TO THIAZIDE DIURETICS (2018), American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 103: S5. doi:10.1002/cpt.993 (PT-001). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
56. S. Singh, **Y. Gong**, C.W. McDonough, K.R. Bailey, A.L. Beitelshes, E. Boerwinkle, A.B. Chapman, J.G. Gums, S.T. Turner, R.M. Cooper-DeHoff, J.A. Johnson. GENOME WIDE ASSOCIATION STUDY IDENTIFIES NOVEL PHARMACOGENETIC VARIANTS ASSOCIATED WITH CHLORTHALIDONE BLOOD PRESSURE RESPONSE IN AFRICAN AMERICANS (2018), American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 103: S50. doi:10.1002/cpt.993 (PI-139). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
57. Shahin MH, Conrado DJ, Gonzalez D, **Gong Y**, Lorbmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. GENOME-WIDE META-ANALYSES REVEAL NOVEL PREDICTORS OF HEART RATE RESPONSE TO β -BLOCKERS IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDIES. Clinical Pharmacology & Therapeutics 2018; 103: S15. (PI-001). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
58. Shahin MH, Conrado DJ, Gonzalez D, **Gong Y**, Lorbmeyer MT, Beitelshes AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. β 2-ADRENERGIC RECEPTOR GENE AFFECTS THE NEGATIVE CHRONOTROPIC EFFECTS OF β -BLOCKERS IN THE PEAR AND PEAR2 STUDIES. Clinical Pharmacology & Therapeutics 2018; 103: S15. (PI-002). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
59. Magvanjav O, McDonough CW, **Gong Y**, Cooper-DeHoff RM, Hogan WR, Johnson JA. Combination antihypertensive therapy prescribing among outpatients: Evidence from an electronic health records database. Clinical Pharmacology & Therapeutics 2018, 103: S1 (PI-112). Abstract presented at the American Society for Clinical Pharmacology and Therapeutics 2018 Annual Meeting; March 22, 2018; Orlando, FL.
60. Magvanjav O, **Gong Y**, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshes AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Towards precision therapy in hypertension: Genome-wide association study reveals genetic variants associated with uncontrolled blood pressure on thiazide diuretic/ β -blocker combination therapy in the Pharmacogenomic Evaluation of Antihypertensive Responses trial. PgmNr 2713/W. Presented at the 67th Annual Meeting of The American Society of Human Genetics, October 18th, 2017 in Orlando, Florida.

61. Mohamed Shahin, Akoluk A, Singh S, McDonough CW, **Gong Y**, Chapman AB, Turner ST, Gums JG, Beitelshes AL, Boerwinkle E, Cooper-DeHoff RM, Johnson JA. A Genome-Wide Association study identifies novel genetic signatures associated with Thiazide diuretics adverse metabolic events. PgmNr 2678/T. Presented at the 67th Annual Meeting of The American Society of Human Genetics, October 19th, 2017 in Orlando, Florida.
62. Singh S, **Gong Y**, McDonough CW, Bailey KR, Beitelshes AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide Association study reveals novel genetic markers associated with Chlorthalidone blood pressure response. PgmNr 2685/F. Presented at the 67th Annual Meeting of The American Society of Human Genetics, October 20th, 2017 in Orlando, Florida.
63. Yang G, Hamadeh IS, Katz J, Riva A, Langae TY, Moreb JS, **Gong Y**. *S/RT1* SNPs associated with bisphosphonate-related osteonecrosis of the jaw (ONJ). Poster presented at American Society of Bone and Mineral Research (ASBMR) # FR0003, Sep 8, 2017 in Denver, Colorado.
64. Arwood AM, McDonough CW, Cavallari LH, Elsey AR, Frye RF, **Gong Y**, Langae TY, Johnson JA, Weitzel KW. Equipping Health professional students to apply pharmacogenomic data to clinical decision making in real-world scenarios: comparison of an active engagement versus didactic teaching approach. Poster presented at Translational Science 2017 in Washington DC, April 19-21, 2017.
65. Chintan S, **Gong Y**, Szady A, Sun Qian, Pepine CJ, Langae T, Lucas AR, Moreb JS. Unanticipated cardiotoxicity due to targeted anticancer therapy in hematologic malignancies patients: Natural history and risk factors. *Cancer Research* 07/2017; 77(13 Supplement):987-987. Podium presentation at the American Association of Cancer Research (AACR) 2017 Annual Meeting in Washington DC, April 2, 2017.
66. Wokhlu A, **Gong Y**, Cooper-DeHoff RM, Smith SM, Handberg EM, Pepine CJ. Relationship between Diastolic Blood Pressure and All-Cause Mortality with Lower Systolic Blood Pressure among Hypertensive CAD patients: Long-term Follow-up of the US Cohort of the INternational VEramapril-SR Trandolapril Study (INVEST). *J Am Coll Cardiol.* 2017; 69 (11):1685. Poster presentation at the American College of Cardiology's 66th Annual Scientific Session in Washington DC on March 19, 2017.
67. **Gong Y**, Nguyen HK, Szady A, Hamadeh I, Lipori G, Sun Q, Cooper-DeHoff RM, Langae TY, Shah C, Pepine CJ, Lucas AR, Moreb J. Cardiomyopathy Associated with Targeted Anticancer Therapies in Electronic Health Records. *J Am Coll Cardiol.* 2017; 69 (11):925. Poster presentation at the American College of Cardiology's 66th Annual Scientific Session in Washington DC on March 19, 2017.
68. Hamburg R, **Gong Y**, Moreb J, Pepine CJ, Lucas A, Szady A. Global longitudinal strain in patients with new left ventricular systolic dysfunction after anticancer targeted therapy. *J Am Coll Cardiol.* 2017; 69 (11):821. Poster presentation at the American College of Cardiology's 66th Annual Scientific Session in Washington DC on March 18, 2017.

69. El Rouby N, McDonough CW, **Gong Y**, McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Bradford Y, Crawford DC, Ritchie MD, Gitzendanner MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Benavente OR, DeHoff RM, Johnson JA. A GWAS of Resistant Hypertension in the International Verapamil SR-Trandolapril Study (INVEST) and Secondary Prevention of Small Subcortical Strokes (SPS3). *Clinical Pharmacology & Therapeutics* 2017; 101:S27. (PI 029). Poster presentation at 2017 Annual Meeting, Washington Marriott Wardman Park, Washington, DC, March 15–18, 2017
70. Singh S, Alghamdi W, Arwood MJ, Bargal SA, de Oliveira F, Dumeny L, Wen-Yi L, Mehanna M, Stockard B, Yang G, Fredette N, Shahin M, Bailey KR, Beitelshes AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, **Gong Y**, McDonough CW, Cooper-DeHoff RM, Johnson JA. A Genome Wide Association Study to Identify Pharmacogenomic Variants Associated with Chlorthalidone Induced Glucose Change in African Americans. American Society for Clinical Pharmacology and Therapeutics. *Clinical Pharmacology & Therapeutics* 2017; 101:S9. (PT-019). This abstract was among the top-scored abstracts submitted this year to the ASCPT conference and was selected to receive ASCPT presidential trainee award.
71. Shahin MH, Michailidis G, **Gong Y**, Beitelshes AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Thiazide-Induced Hyperuricemia: Novel Insights from Metabolomics and Genomics Integration in the Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR2) Study. *Clinical Pharmacology & Therapeutics* 2017; 101: S13. (PT-028). This abstract was among the top-scored abstracts submitted this year to the ASCPT conference and was selected to receive ASCPT presidential trainee award.
72. Costa Sa A, Webb A, **Gong Y**, McDonough CW, Shahin MH, Datta S, Langae TY, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. RNA-Seq Analyses Identify Molecular Markers of Blood Pressure (BP) Response to Thiazide Diuretics (TD). *Clinical Pharmacology & Therapeutics* 2017; 101:S96. (PWIV-001). Poster Walk presentation at the 2017 American Society of Clinical Pharmacology and Therapeutics Meeting, Washington, DC, March 15-18, 2017.
73. Cavallari LH, Denny JC, Lee CR, Beitelshes AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, **Gong Y**, Wei WQ, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff RM, Dave CV, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Kreutz RP, Stouffer GA, Wilke RA, Empey PE, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective Clinical Implementation of CYP2C19-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting. *Circulation* 2016;134: e711-712 (abstract #21050). Presented as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines at the American Heart Association's Scientific Sessions 2016. New Orleans, LA. November 15, 2016.
74. Lovato B, Weitzel W, Elsey A, McDonough C, **Gong Y**, Fillingim R, Schmidt S, Johnson J, Cavallari L. Factors influencing beliefs about pharmacogenetics testing in patients with chronic pain. *Pharmacotherapy* 2016;36(10):e144 (#455). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL.

75. Bargal S, Kight J, de Oliveira F, Shahin M, Langaee T, **Gong Y**, Hamadeh I, Cooper-DeHoff R, Cavallari L. Implications of polymorphisms in BCKDK and GATA-4 genetic regions on stable warfarin dose in African Americans. *Pharmacotherapy* 2016;36(12):e267 (#250). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL.
76. Mehanna M, **Gong Y**, McDonough CW, Beitelshes A, Gums J, Chapman AB, Johnson J, Turner S, Cooper-DeHoff R. The role of plasma renin activity for improving precision of antihypertensive drug therapy in European Americans and African Americans. *Pharmacotherapy* 2016;36(12):e214 (#40). Poster presentation at the ACCP Annual Meeting. October 23-26, 2016. Hollywood, FL.
77. Elgendi I, Bavry A, **Gong Y**, Handberg E, Cooper-DeHoff RM, Pepine CJ. Long-term mortality in a cohort of hypertensive patients with Coronary Artery disease: results from an extended follow up of the International Verapamil/Trandopril study (INVEST) Project. *J Am Coll Cardiol.* 2016; 67(13_S):2015-2015. Poster presentation at the American College of Cardiology in Chicago. April 4, 2016.
78. O. Magvanjav, C. W. McDonough, **Y. Gong**, L. A. McClure, R. L. Talbert, R. B. Horenstein, B. D. Mitchell, A. R. Shuldiner, O. R. Benavente, J. A. Johnson. Pharmacogenetic association of β 1-adrenergic receptor Ser49Gly polymorphism with outcomes in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. *Clinical Pharmacology & Therapeutics* 2016, 99: S19 (PT-17). March 12, 2016. San Diego, FL.
79. A. C. Sa, A. Webb, **Y. Gong**, C.W. McDonough, M.H. Shahin, T. Y. Langaee, S.T. Turner, A. L. Beitelshes, A. B. Chapman, E. Boerwinkle, J.G. Gums, S. Scherer, R. M. Cooper-DeHoff, W. Sadée, J. A. Johnson. Hypertension (HTN)/Blood Pressure (BP) Signature Genes and BP Response to Thiazide Diuretics (TD): Results From Pear and Pear-2 Studies. *Clinical Pharmacology & Therapeutics* 2016, 99: S19 (PT23). Poster and Oral presentation at the American Society of Clinical Pharmacology and Therapeutics. March 10, 2016. San Diego, FL
80. M. H. Shahin, A.C. Sa, A. Webb, **Gong Y**, T. Langaee, C. W. McDonough, A. Riva, A. L. Beitelshes, A. B. Chapman, J. G. Gums, S. T. Turner, R. F. Frye, S. E. Scherer, W. Sadée, R. M. Cooper-DeHoff, J. A. Johnson. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics* 2016, 99: S19. Poster presentation at the American Society of Clinical Pharmacology and Therapeutics. March 9, 2016. San Diego, FL
81. Mohamed H Shahin, Daniel M Rotroff, Amy Webb, **Gong Y**, Taimour Langaee, Caitrin W McDonough, Amber L Beitelshes, Timothy Garrett, John G Gums, Alison Motsinger-Reif, Arlene B Chapman, Stephen T Turner, Eric Boerwinkle, Reginald F Frye, Steven E Scherer, Wolfgang Sadée, Oliver Fiehn, Rhonda M Cooper-DeHoff, Rima Kaddurah-Daouk, and Julie A Johnson. Integrating Metabolomics and Genomics Uncovers Novel Pathways and Genetic Signatures Influencing Hydrochlorothiazide Blood Pressure Response: A Genetic Response Score for Hydrochlorothiazide Use. *Circulation* 2015;132:A13621. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 8, 2015. Orlando, FL.

82. de Oliveira FA, Shahin MH, **Gong Y**, McDonough CW, Beitelshes AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Genomics-metabolomics Integrative Approach Reveals Novel Biomarkers in DPYS Associated With Higher Glucose Change After Treatment With Atenolol. *Circulation* 2015;132:A18338. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 10, 2015. Orlando, FL.
83. N. El Rouby, C. W. McDonough, **Gong Y**, L. A. McClure, B. D. Mitchell, R. B. Horenstein, R. L. Talbert, A. Takahashi, T. Tanaka, M. Kubo, C. J. Pepine, R. M. Cooper-DeHoff, O. R. Benavente, A. R. Shuldiner, J. A. Johnson. Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). *Circulation* 2015;132:A15465. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 9, 2015. Orlando, FL.
84. Cavallari LH, Magvanjav O, Anderson RD, **Gong Y**, Owusu-Obeng A, Kong B, Vo T, Ashton JN, Staley BJ, Elsey AR, Allan RW, Starostik P, Cooper-DeHoff RM, Weitzel KW, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical implementation of CYP2C19 genotype guided antiplatelet therapy reduces cardiovascular events after PCI. *Circulation* 2015;132:A11802. Poster presentation at the American Heart Association 2015 Scientific Sessions. November 9, 2015. Orlando, FL.
85. N. El Rouby, C. W. McDonough , **Y. Gong** , L. A. McClure , B. D. Mitchell, R. B. Horenstein, R. L. Talbert, A. Takahashi, T. Tanaka, M. Kubo, C. J. Pepine, R. M. Cooper-DeHoff, O. R. Benavente, A. R. Shuldiner, J. A. Johnson. Novel genetic loci for resistant hypertension discovered through a genome-wide association approach (GWAS) in the INternational VErapamil SR-Trandolapril STudy (INVEST) and the Secondary Prevention of Subcortical Strokes (SPS3) Study. Program/Abstract # 665. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 8th, 2015 in Baltimore, MD.
86. M. H. Shahin , A. C. Sa , A. Webb , **Y. Gong** , T. Langae , C. W. McDonough , A. L. Beitelshes , A. B. Chapman , J. G. Gums , S. T. Turner , R. F. Frye , S. E. Scherer , W. Sadée , R. M. Cooper-DeHoff , J. A. Johnson. Identifying a Novel Hypertension Genetic Signature Influencing the Blood Pressure Response to Hydrochlorothiazide Treated Patients. Program/Abstract #674. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.
87. A. C. Sa, A. Webb, **Y. Gong**, C. W. McDonough, T. Y. Langae, S. T. Turner, A. L. Beitelshes, A. B. Chapman, E. Boerwinkle, J. G. Gums, S. Scherer, R. M. Cooper-DeHoff, W. Sadée, J. A. Johnson. Molecular Markers of Blood Pressure Response to Thiazide Diuretics Identified Through Whole Transcriptome RNA-Seq Analysis, Program/Abstract #656. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.
88. **Gong Y**, Katz J, Riva A, Davis N, Hamadeh IS, Bella Bernadett, Kosa J, Vaszik M, Pelliccioni GA, Lakatos P, Moreb J, Langae TY. Genetic variants associated with bisphosphonate-associated osteonecrosis of the jaw: A whole-Exome sequencing study. Poster presented at

American Society of Bone and Mineral Research (ASBMR) # S121, Oct 10th, 2015 in Seattle, WA.

89. Solayman MH, Langaee T, **Gong Y**, El-Hamamsy M, El-Wakeel L, Boerwinkle E, Chapman A, Turner S, Gums J, Beitelshes A, Cooper-DeHoff R, Badary O, Johnson JA. Association of Plasma MicroRNA with Antihypertensive Response to Beta Blockers. Clinical Pharmacology in Drug Development. 2015; 4(S1) 58-59, DOI: 10.1002/cpdd.216.
90. M.H. Shahin, **Y. Gong**, T. Langaee, A.L. Beitelshes, D.M. Rotroff, A.B. Chapman, J.G. Gums, S.T. Turner, A. Motsinger-Reif, R.F. Frye, O. Fiehn, J.A. Johnson, R. Cooper-DeHoff, X. Han, R. Kaddurah-Daouk. Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. (2015), Poster Session I. Clinical Pharmacology & Therapeutics, 97: S21–S56. doi:10.1002/cpt.50.
91. M. H. Shahin, D. M. Rotroff, **Y. Gong**, T. Langaee, C. W. McDonough, A. L. Beitelshes, T. J. Garrett, A. B. Chapman, J. G. Gums, S. T. Turner, A. Motsinger-Reif, R. F. Frye, S. E. Scherer, W. Sadee, O. Fiehn, R. M. Cooper-DeHoff, R. Kaddurah-Daouk, J. A. Johnson. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (Pear) Study. (2015), Presidential Trainee Awards. Clinical Pharmacology & Therapeutics, 97: S11–S18. doi: 10.1002/cpt.48.
92. M. H. Shahin, D. M. Rotroff, **Y. Gong**, T. Langaee, C. W. McDonough, A. L. Beitelshes, T. J. Garrett, A. B. Chapman, J. G. Gums, S. T. Turner, A. Motsinger-Reif, R. F. Frye, S. E. Scherer, W. Sadee, O. Fiehn, R. M. Cooper-DeHoff, R. Kaddurah-Daouk, J. A. Johnson. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (Pear) Study. (2015), Oral Session III. Clinical Pharmacology & Therapeutics, 97: S103–S104. doi:10.1002/cpt.56.
93. S. Chang, **Y. Gong**, C.W. McDonough, N. Nasiri Kenari, T. Langaee, A.L. Beitelshes, J.G. Gums, A.B. Chapman, S.T. Turner, J.A. Johnson, R.M. Cooper-DeHoff. CORRELATING THE MELATONIN (MT) PATHWAY WITH ATENOLOL ASSOCIATED GLUCOSE DYSREGULATION IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY. Presidential Trainee Awards. *Clin. Pharmacol. Ther.*, 2015 97: S17. doi:10.1002/cpt.48. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 7, 2015. New Orleans, LA.
94. Smith MS, Huo T, **Gong Y**, Handberg EM, Gulati M, Merz NB, Pepine CJ, Cooper-DeHoff RM. Mortality and Cardiovascular risk associated with apparent treatment-resistant hypertension among women. *Circulation* 2014;130: A17677.
95. Kawaguchi-Suzuki M, Bril F, Cusi K, Langaee T, **Gong Y**, Frye RF. Role of Genetic Polymorphisms on the Improvement of Liver Histology after Pioglitazone Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). *Hepatology* 2014;60(S1):591A. DOI: 10.1002/hep.27514.

96. El Rouby N, McDonough CW, **Gong Y**, Pepine CJ, Takahashi A, Tanaka T, Kubo M, Cooper-DeHoff RM, Johnson JA. Genome-wide Association Study of Resistant Hypertension in INVEST. Abstract/Program 702M. Poster presented at the 64th Annual Meeting of The American Society of Human Genetics, October 20, 2014 in San Diego, CA.
97. Sa ACC, Webb A, **Gong Y**, Langaee TY, Turner ST, Chapman AB, Gums JG, Scherer S, Cooper-DeHoff RM, Sadee W, Johnson JA. Identifying Differentially Expressed Genes Associated with Extreme Blood Pressure Response to Hydrochlorothiazide monotherapy. Abstract/Program 732M. Poster presented at the 64th Annual Meeting of The American Society of Human Genetics, October 20, 2014 in San Diego, CA.
98. Bavry AA, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. IS ASPIRIN BENEFICIAL FOR ALL PATIENTS WITH CHRONIC STABLE CORONARY ARTERY DISEASE? *J American College of Cardiology* 2014 Apr, 63 (12_Supplement) A1564. Poster presentation at ACC.
99. **Gong Y**, McDonough CW, Wang Z, Langaee TY, Beitelshes AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive Responses Study. *Clin Pharmacol Ther* 2014; 95 (S1): S16. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
100. McDonough CW, **Gong Y**, Langaee TY, Pepine CJ, Cooper-DeHoff RM, Johnson JA. A Pharmacogenomic Genome-wide Association Study for Adverse Cardiovascular Outcomes in the International Verapamil Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2014; 95 (S1): S71. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 21, 2014 Atlanta, GA.
101. Chang S, McDonough CW, **Gong Y**, Pepine CJ, Johnson JA, Cooper-DeHoff RM. A Pharmacogenomic Genome-wide Association Study (GWAS) for New onset diabetes in the International Verapamil SR-Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2014; 95 (S1): S59. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
102. Fontana V, McDonough CW, **Gong Y**, ElRouby NM, Sa AC, Pepine CJ, Cooper-DeHoff RM, Johnson JA. ATP2B1 Locus is associated with resistant Hypertension in the International Verapamil trandolapril Study-Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2014; 95 (S1): S26. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
103. Hamadeh IS, Langaee TY, **Gong Y**, Skaar TC, Johnson JA. Impact of CYP2D6 Polymorphisms on Clinical Response and Tolerability of Immediate Release Metoprolol. *Pharmacotherapy*. 2013 (10): E232-E232.

104. Erdine S, Pepine CJ, Mancia G, **Gong Y**, Butev F. Efficacy of Calcium Antagonist vs. Non-calcium Antagonist Strategy in Reduction of Heart Rate in Diabetic Hypertensive Patients with Coronary Artery Disease: Data from INVEST Study. *Journal of Hypertension*. 2013 (31): e194.
105. Erdine S, Pepine CJ, Mancia G, **Gong Y**, Butev F. The Efficacy of Calcium Antagonist vs. Non-calcium Antagonist Strategy in Reduction of Heart Rate in Hypertensive Patients with Coronary Artery Disease: Data from INVEST Study. *Journal of Hypertension*, 2013 (31): e333.
106. **Gong Y**, Moore MJ, Karnes JH, McDonough CW, Wang Z, Langae TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Johnson JA, Cooper-DeHoff RM. Fasting Glucose Loci Associated with Glucose Response to Antihypertensives-Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). *Clin Pharmacol Ther* 2013; 93 (S1): S28. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 7, 2013 Indianapolis, IN.
107. Cooper-DeHoff RM*, Hou W, Baillie R, Beitelshes AL, **Gong Y**, Chapman AB, Gums JG, Turner ST, Boyle SH, Zhu H, Wikoff WR, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Pharmacometabolomics reveals a novel signature for predicting beta blocker associated impaired fasting glucose. *Circulation*. 2012;126:A11088. Poster presentation at American Heart Association. Nov 20, 2012, Los Angeles, CA.
108. Winchester DE, **Gong Y**, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Mortality associated with angina and blood pressure control among hypertensive patients with coronary artery disease: new data from extended follow-up of the INternational VErapamil SR-Trandolapril STudy. *J American College of Cardiology* 2012; 59 (13): E1458. Poster presentation at ACC.
109. Bavry AA, **Gong Y**, Kumbhani DJ, Kowey P, Haththotuwa E, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Predictors of Mortality among Patients with Hypertension and Coronary Artery Disease: the INternational VErapamil SR-Trandolapril STudy (INVEST). *J American College of Cardiology* 2012; 59 (13): E1496. Poster presentation at ACC.
110. Cooper-DeHoff RM, **Gong Y**, Handberg EM, Messerli F, Bakris G, Bavry AA, Pepine CJ. Treatment-Resistant Blood Pressure among Patients with Coronary Artery Disease-Cause for Concern: New data from the Extended Follow-up of the INternational VErapamil SR-Trandolapril STudy (INVEST). *J American College of Cardiology* 2012; 59 (13): E1498. Poster presentation at ACC.
111. **Gong Y**, McDonough CW, Wang Z, Cooper-DeHoff RM, Langae TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S16. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.

112. Moore MJ, **Gong Y**, Schmidt S, Hall K, Chapman AB, Langae TY, Gums JG, Coop-DeHoff RM, Johnson JA. ANTIHYPERTENSIVE MEDICATION EXPOSURE AND ADVERSE GLYCEMIC EFFECTS: AN EVALUATION OF FASTING AND STIMULATED GLUCOSE, *Clin Pharmacol Ther* 2012; 91 (S1): S25. Podium presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
113. Moore MJ, **Gong Y**, Hou W, Chapman AB, Langae TY, Schwartz GL, Turner ST, Gums JG, Bailey K, Boerwinkle E, Beitelshes AL, Coop-DeHoff RM, Johnson JA. CLINICAL PREDICTORS OF DYSGLYCEMIC EFFECTS ASSOCIATED WITH USE OF BETA BLOCKERS AND THIAZIDE DIURETICS. *Clin Pharmacol Ther* 2012; 91 (S1): S24. Podium presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
114. McDonough CW, Burkley B, **Gong Y**, Langae TY, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Non-synonymous SNPs in *SELE*, *SELP*, and *SIGLEC12* associate with cardiovascular (CV) outcomes in the INternational VErapamil SR-Trandolapril STudy GENetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2012; 91 (S1): S20. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
115. Karnes JH, McDonough CW, **Gong Y**, Langae TY, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Alpha adducin-1 (*ADD1*) Single nucleotide polymorphism (SNP) Associated with new onset diabetes risk with Hydrochlorothiazide (HCTZ) therapy in the International verapamil sr trandolapril study (INVEST). *Clin Pharmacol Ther* 2012; 91 (S1): S21. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
116. Vandell AG, McDonough CW, Langae TY, Burkley B, **Gong Y**, Turner ST, Gums JG, Chapman AB, Beitelshes AL, Cooper-DeHoff RM, Johnson JA. Association of *FTO* with Hydrochlorothiazide (HCTZ)-induced elevation in uric acid (UA) in African American (AA) hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) study. *Clin Pharmacol Ther* 2012; 91 (S1): S59. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
117. Karnes JH, Vo TT, **Gong Y**, Langae TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Pepine CJ, Johnson JA, Cooper-DeHoff RM. *KCNJ1* SNPs are Associated with Increased Fasting Glucose and Risk of New Onset Diabetes during HCTZ Therapy. *Clin Pharmacol Ther* 2011; 89(S1):S46. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
118. Vandell AG, Lobmeyer MT, Gawronski B, Langae TY, **Gong Y**, Beitelshes AL, Gums JG, Turner ST, Chapman AB, Cooper-DeHoff RM, Liggett SB, Johnson JA. Influence of G Protein Receptor Kinase 4 (GRK4) Polymorphisms on Blood Pressure Response to the Beta-blocker Atenolol. *Clin Pharmacol Ther* 2011; 89(S1):S74. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
119. Davis HM, **Gong Y**, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Genetic Variation in the Calcium Signaling Pathway and Association with Outcomes in Hypertensive Coronary Artery

- Disease Patients. *Clin Pharmacol Ther* 2011; 89(S1):S20. Poster presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting.
120. **Gong Y**, Beitelshes AL, Lobmeyer MT, Langae TY, Cooper-DeHoff RM, Wu J, Spertus JA, Province MA, Pepine CJ, Johnson JA. Chromosome 9p21 SNPs Haplotypes are Associated with Cardiovascular Outcomes in Patients with Coronary Artery Diseases. *Circulation* 2010;122:A16925. Oral presentation at American Heart Association Scientific session.
121. Bavry AA, Khaliq A, **Gong Y**, Handberg EM, Cooper-DeHoff RM, Pepine CJ. Effects of Chronic Nonsteroidal Anti-inflammatory Drugs among Patients with Hypertension and Coronary Artery Disease: Post Hoc Analysis from the INVEST Trial. *Circulation* 2010;122:A12424
122. Shroads AL, Langae TY, Coats BS, Kurtz TL, Bullock J, Weithorn D, **Gong Y**, Wagner D, Ostrov DA, Johnson JA, Stacpoole PW. Human Polymorphisms in the Glutathione Transferase Zeta 1 Maleylacetooacetate Isomerase Gene Predict the Kinetics and Toxicity of Dichloroacetate. *Drug Metabolism Reviews*. 2010; 42: 204.
123. Karnes JH, George AM, **Gong Y**, Langae TY, Stauffer LA, Burkley BM, Pepine CJ, Johnson JA, Cooper-DeHoff RM. New Onset Diabetes Risk Associated with Antihypertensive Therapy in Hypertensive Coronary Artery Disease Patients is Modified by a Single Nucleotide Polymorphism in the L-type Calcium Channel Alpha 1c Subunit (CACNA1C). *Clin Pharmacol Ther* 2010;87(S1):S45
124. Moore MJ, Chik VPW, **Gong Y**, Langae TY, Chapman AB, Schwartz GL, Turner ST, Gums JG, Cooper-DeHoff RM, Beitelshes AL, Johnson JA. Association between Melatonin Receptor 1B Single Nucleotide Polymorphisms (SNPs) and Response to Antihypertensive Drugs. *Clin Pharmacol Ther* 2010;87(1):S45
125. Davis HM, Allen B, **Gong Y**, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Clinical Association of Variation in the β2 Regulatory Subunit of the Voltage-Gated Calcium Channel (CACNB2) with Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther* 2010;87(1):S2
126. Cooper-DeHoff RM, **Gong Y**, Marin J, Rosen A, Handberg EM, Johnson JA, Pepine CJ. Long-Term Mortality Associated With New Onset Diabetes in Hypertensive CAD Patients Following Exposure to Antihypertensive Medications: Findings from the INternational VErapamil SR-Trandolapril STudy (INVEST). *J American College of Cardiology* 2009;53:A224
127. Winchester DE, **Gong Y**, Handberg EM, Cooper-Dehoff RM, Pepine CJ. Incident or Continued Angina During Hypertension Treatment is Associated With Increased Risk of Death, MI, or Stroke Among Patients With Known CAD: A Substudy of The INternational VErapamil/Trandolapril STudy (INVEST). *Circulation* 2009;120:S440

128. Niu Y, Langaee TY, **Gong Y**, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. DNA Variations in Voltage-gated Calcium Channel Beta 2 Subunit (CACNB2) Gene, Functional Consequences, and Association with Adverse Cardiovascular Outcomes in the INternational VErapamil SR-trandolapril STudy-GENEtic Substudy. *Circulation* 2008;118(18):S885
129. Hassan M, York KM, Li HH, Li Q, **Gong Y**, Langaee TY, Fillingim RB, Johnson JA, Sheps DS. B1-adrenergic Receptor Polymorphism Predicts Mental Stress-induced Myocardial Ischemia in Patients with Coronary Artery Disease. *J American College of Cardiology* 2008;51:A377
130. Navare HA, Beitelishees AL, **Gong Y**, Langaee TY, Cooper-Dehoff RM, Pepine CJ, Johnson JA. CACNA1C Polymorphisms and Cardiovascular Outcomes in the INternational VErapamil SR/Trandolapril STudy-Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2008;83(S1):S4
131. Pacanowski MA, Cooper-DeHoff RM, **Gong Y**, Schork NJ, Pepine CJ, Johnson JA. Diabetes Risk Associated with β_1 -adrenergic Receptor Polymorphisms Differs by Antihypertensive Drug Therapy: Results from the INternational VErapamil SR/trandolapril STudy – GENEtic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2008;83(S1):S83
132. Johnson AD, **Gong Y**, Wang D, Langaee TY, Shin J, Cooper-DeHoff RM, Schork NJ, Shriver MA, Binkley P, Pepine CJ, Johnson JA, Sadee W. Novel Promoter Polymorphisms in Angiotensin-I Converting enzyme (ACE) Associated with Clinical Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther* 2008;83(S1):S8
133. Denardo SJ, Messerli FH, Aranda JM, Cooper-DeHoff RM, Handberg EM, **Gong Y**, Champion A, Pepine CJ. Association of 'J-shaped' Curves and Age: A Substudy of the International Verapamil SR-Trandolapril Study (INVEST). *Circulation* 2008; 118 (18): S1160
134. Shin J, Kline S, Moore M, **Gong Y**, Blianderi V, Schmalfuss CM, Schofield RS, Johnson JA. Diurnal Blood Pressure Pattern is Associated with Risk for Hospitalization or Death in Heart Failure. *Clini Pharmacol Ther* 2007;81:S15
135. Schentrup AM, Nino G, **Gong Y**, Lima JJ, Cooper-Dehoff RM, Pepine CJ, Johnson JA. LTA4H Variant Confers Drug Therapy-dependent Reduced Risk of Cardiovascular Events in INVEST (INternational VErapamil SR/Trandolapril STudy). *Clin Pharmacol Ther* 2007;81:S35
136. Pacanowski MA, **Gong Y**, Langaee TY, Cooper-DeHoff RM, Schork NJ, Pepine CJ, Johnson JA. Beta 2-adrenergic Receptor Polymorphisms and Antihypertensive Treatment Outcomes in the INternational VErapamil SR/Trandolapril STudy-GENEtic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2007;81:S34
137. Langaee TY, Burkley B, **Gong Y**, Zineh I. Effects of CYP3A4 and CYP3A5 polymorphisms on cholesterol responses to atorvastatin. *Clin Pharmacol Ther* 2007;81:S89

138. Cooper-Dehoff RM, Gerhard T, **Gong Y**, Handberg EM, Messerli FH, Pepine CJ. Blood Pressure < 120/80 mm Hg is Risky in Elderly CAD Patients: Findings from the INternational VErapamil SR-Trandolapril STudy (INVEST). *Circulation* 2007;115:E258
139. Gerhard T, **Gong Y**, Beitelshes AL, Cooper-DeHoff RM and Johnson JA. Association between CV Outcomes, Diuretic use and the Alpha-adducin Gene: Results from the INternational VErapamil SR Trandolapril STudy (INVEST). *Pharmacoepidemiology and Drug Safety* 2006;15:S17-S18
140. **Gong Y**, Handberg EM, Gerhard T, Cooper-DeHoff RM, Johnson JA, Pepine CJ. Association of Systolic Blood Pressure (SBP) and Health Related Quality of Life in Patients with Coronary Artery Disease: An Analysis from the INternational VErapamil SR Trandolapril STudy (INVEST). *Circulation* 2006;114(8):576-577
141. Handberg E, **Gong Y**, DeHoff RC, Ried LD, Pepine CJ. Can An Assessment of Subjective Well Being Predict Outcomes in Patients with Hypertension and Coronary Artery Disease? A Report from the INternational VErapamil-SR/Trandolapril STudy (INVEST). *Journal of the American College of Cardiology* 2006;47(4):300A
142. Johnson JA, Karnes JH, Brunner M, **Gong Y**, Langaee TY, Cooper-DeHoff RM, Pepine CJ. Lack of Association of the Angiotension II Type I Receptor (AGTR1) 1166 A>C Polymorphism with Cardiovascular and Cerebrovascular Outcomes in Subgroup of Patients of the INternational VErapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P43
143. Lobmeyer MT, Terra SG, **Gong Y**, Hamilton KK, Pauly DF, Patterson JH, Adams KF, Schofield RS, Hill JA, Aranda JM, Johnson JA. Synergistic Polymorphisms of β 1- and α 2C-Adrenergic Receptors and the Influence on Left Ventricular Ejection Fraction in Response to β -blocker Therapy in Heart Failure. *Clin Pharmacol Ther* 2006;79(2):P31
144. Shin J, Lobmeyer MT, **Gong Y**, Zineh I, Langaee TY, Yarandi HN, Pauly DF, Aranda JM, Schofield RS, Hill JA, Johnson JA. A Haplotype of β 2-adrenoceptor is Associated with the Increased Risk for Transplant or Death in Heart Failure Patients. *Clin Pharmacol Ther* 2006;79(2):P30
145. Brunner M, Karnes JH, **Gong Y**, Langaee TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of Angiotension II Type I Receptor (AGTR1) 1166A>C Polymorphism with Blood Pressure Response to ACE inhibitor in a Subgroup of Patients of the INternational VErapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P14
146. Beitelshes AL, **Gong Y**, Cooper-DeHoff RM, Burt L, Stauffer LA, Pepine CJ, Johnson JA. KCNMB1 Genotype Associated with Cardiovascular Outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P41
147. **Gong Y**, Beitelshes AL, Stauffer LA, Langaee TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Beta Adrenergic Receptors Polymorphisms are Associated with Response to

Beta-Blocker Therapy in the INternational VErapamil SR-Trandolapril STudy (INVEST). *Clin Pharmacol Ther* 2006;79(2):P30

148. Gerhard T, **Gong Y**, Beitelshees AL, Lohmeyer M, Schiebelbein L, Langaele TY, Cooper-DeHoff RM and Johnson JA. Association between CV Outcomes, Diuretic use and the Alpha-adducin gene: Results from the INternational VErapamil SR Trandolapril STudy (INVEST). *Circulation* 2005;112(17):U670
149. Zoo J, Vergara S, Chen S, Jiang J, Kaku M, Kohno S, **Gong Y**, Hurst I, Huang H, Holliday L. Characterization of the Actin-binding Activity of Subunit B of Vacuolar H⁺-ATPases. *Journal of Bone and Mineral Research* 2005;20(9):S258-S258
150. Beitelshees AL, **Gong Y**, Cooper-DeHoff RM, Moss JI, Pepine CJ, Johnson JA. Variable blood pressure response to verapamil by KCNMB1 genotype. *Clin Pharmacol Ther* 2005;77(2):97
151. **Gong Y**, Beitelshees AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, Langaele TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Beta 2-adrenergic Receptor (B2AR) Polymorphisms and Antihypertensive Response to Beta-blocker Therapy in the INVEST Trial. *Clin Pharmacol Ther* 2005;77(2):22
152. King MA, **Gong Y**, Meyers C, Hughes JA and Meyer EM. Localized Gene Transfer of K670N/M671L App into Rat Hippocampus Produces Mnemonic Deficits, Neuronal Degeneration, and Alpha7 Nicotinic Receptor Alterations. *Neurobiology of Aging* 2004;25:S225
153. Jiang J, Zuo J, **Gong Y**, Hurst IR, Holliday LS. Role of Phosphatidylinositol 3-Kinase (p110 alpha) in Osteoclasts. *Journal of Bone and Mineral Research* 2003;18:S237

INVITED PRESENTATIONS:

1. 03/19/2006. 'Beta Adrenergic Receptors Polymorphisms are Associated with Response to Beta-Blocker Therapy in the INternational VErapamil SR-Trandolapril STudy (INVEST).' American Society for Clinical Pharmacology and Therapeutics Annual meeting.
2. 11/14/2006, Association of Systolic Blood Pressure (SBP) and Health Related Quality of Life in Patients with Coronary Artery Disease: An Analysis from the INternational VErapamil SR Trandolapril STudy (INVEST). American Heart Association Scientific session.
3. 11/16/2010, 'Chromosome 9p21 SNPs Haplotypes are Associated with Cardiovascular Outcomes in Patients with Coronary Artery Diseases.' American Heart Association Scientific session, Chicago, IL.
4. 12/14/2011, 'GWAS, Expression and Pathway Analysis of Triglyceride Response to Simvastatin Therapy', Pharmacogenomics Research Network, PSTAR analysis workshop, Chicago, IL.
5. 10/12/2012, 'Application of Genetic Risk Scores in Antihypertensive Pharmacogenomics: Essential for Future Clinical Translation.' Pharmacogenomics Research Network Research in Progress Webinar, online

6. 03/20/2014, 'Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive Responses Study'. American Society for Clinical Pharmacology and Therapeutics Annual meeting, Atlanta, GA.

Visiting Scholars Supervised:

Martin Brunner, MD. Medical University of Vienna, Austria. 2005-2006

Vanessa Fontana, PhD. State University of Campinas, Brazil. 2013

Ying Yuan, MD. Affiliated Cancer Hospital of Guangxi Medical University, China. 2016-2017

Postdoctoral Fellows Supervised:

| | |
|--------------------------------|-----------|
| Luba Keilbasa, PharmD. | 2005-2006 |
| Jaekyu Shin, PharmD. | 2005-2007 |
| Michael Pacanowski, PharmD. | 2005-2008 |
| Mohamed Shafiu, MD. | 2008-2009 |
| Maximilian Lobmeyer, PhD. | 2009-2010 |
| Hazem Elewa, PharmD, PhD. | 2009-2010 |
| Alexander Vandell, PharmD/PhD. | 2010-2012 |
| Caitrin McDonough, PhD. | 2010-2013 |
| Murali Munisamy, PhD. | 2012-2013 |
| Issam Hamadeh, PharmD. | 2012-2016 |
| Liming Weng, PhD. | 2013-2015 |
| Arda Akoluk | 2016-2017 |
| Mohamed Shahin | 2016-2018 |
| Sonal Singh | 2015-2019 |
| Eric Pruitt | 2019-2021 |
| Marwa Tantawy | 2019-2023 |

Undergraduate students Supervised:

| | |
|----------|-----------|
| Zheng Li | 2017-2017 |
|----------|-----------|

PharmD students Supervised:

| | |
|-------------------|-----------|
| Hoai Khanh Nguyen | 2016-2017 |
| Cherokie Boyd | 2018-2019 |
| Frances Pamittan | 2019-2020 |
| Nathalie Roumie | 2022-2023 |
| Marion-Ian Javier | 2023-2024 |

Graduate Committee

Committee Chair-PhD:

Guang Yang, 2016 to 2020. Dissertation title: 'Pharmacogenomics of drug induced osteonecrosis of the Jaw'. Current position: Postdoc Fellow, North Western University.

- Awards:

- 2017 ASBMR Young Investigator Travel Award
- 2018 PGRN ASHG Best Trainee Abstract Award
- 2019 ASCPT Presidential Trainee Abstract Award
- 2019 PGRN ASCPT Best Trainee Abstract Award
- 2019 ASBMR Young Investigator Travel Award
- 2020 PGRN Presidential Trainee Abstract Award
- 2021 ASCPT Presidential Trainee Abstract Award

Samia Shabnaz, 2021 to present. Dissertation title: TBD

Committee Member -PhD:

Maximilian Lobmeyer, BS. 2004 to May 2009. Dissertation title: "Genetic Variation of beta-adrenergic receptor kinase 1 and beta-arresting 1: Definition, functional consequences and clinical implications". Current position: Research Scientist, Boehringer Ingelheim.

Julio Duarte, Pharm.D, 2007 to August 2010. Dissertation title: "The Role of the AF9/Dot1a/Sirt1 Candidate Pathway on Patient Variability in Blood Pressure and Cardiometabolic Responses to Hydrochlorothiazide". Current position: Assistant Professor, Department of Pharmacotherapy and Translational Research, University of Florida.

Heather Davis, Pharm.D, 2008 to December 2011. Dissertation title: "Pharmacogenetic Assessment and Molecular Analysis of Calcium Signaling Pathway Variation". Current position: practicing pharmacist.

Jason Karnes, Pharm.D, 2009 to August 2012. Dissertation title: "Genetic, pharmacogenetic, and pharmacotherapeutic risk factors for thiazide-induced dysglycemia". Current position: Assistant Professor, University of Arizona College of Pharmacy.

Mariellen Moore, Pharm.D, 2008 to December 2012. Dissertation title: "Adverse Metabolic Effects of Antihypertensive Medications: Clinical, Genetic, and Molecular Predictors". Current position: practicing pharmacist.

Mohamed Hossam Shahin, 2011 to December 2015. Dissertation title: 'Pharmacogenomics, transcriptomics and metabolomics for the identification of novel predictors associated with blood pressure response'.

Shin-Wen Chang, 2011 to December 2015. Dissertation title: 'Identifying Pharmacogenomic Loci Associated with Antihypertensive Treatment related Glucose Dysregulation and Potential Underlying Mechanism Using Data from Three Clinical Studies'.

Marina Kawaguchi, 2012 to August 2015. Dissertation title: 'Drug disposition and response in nonalcoholic fatty liver disease'.

Ana Caroline Costa Sa, 2012 to August 2017. Dissertation title: 'Transcriptome Profiling in Hypertensive Patients with Extreme Blood Pressure Response to Thiazide Diuretics'.

Nihal El Rouby, 2013 to August 2017. Dissertation title: 'Identification of genetic determinants associated with resistant hypertension using genome-wide association analysis coupled with induced pluripotent stem cells (iPSC)'.

Oyunbileg Magvanjav, 2014 to April 2018. Dissertation title: 'Identifying predictors of difficult-to-treat hypertension through genomics, metabolomics and electronic health records data analyses'.

Bradley Stockard, 2014 to May 2019. Dissertation title: 'Global and Targeted Metabolomics in Pediatric AML Identify Metabolic Differences Associated with Patient Characteristics and Treatment Response.'

Franjo Ivankovic-Macgibbon, 2020 to 2022. Dissertation title: 'Statistical Genetics in Psychiatric Disorders'.

Yimei Huang, 2020 to present. Dissertation title: 'The Impact of Metabolic Syndrome on Heart Failure Including Pulmonary Hypertension as an Indicator.'

Cameron Thomas, 2020 to present. Dissertation title: 'Real-World determinants of P2Y12 inhibitor effectiveness and safety after PCI'.

Noor Nahid, 2020 to present. Dissertation title: 'Impact of CYP2D6 genotypes and inhibitors on opioid therapy in patients with pain'.

Tingting Hou, 2020 to present. Dissertation title: TBD

Chijioke Anyaso-Samuel, 2020 to present. Dissertation title: TBD

Francisco Marchi, 2022 to present. Dissertation title: TBD

Committee Chair -MS:

Trang Nguyen, 2021-2022

Raed Alshammari, 2023-present

Committee Member -MS:

Bin Zhang, MS, 2009

Felipe de Oliveira, MS, 2014-2016

Mai Mehanna, MS, 2015-2017

Wenyi Li, MS, 2016-2018

Shaimaa Elbalkiny, MS, 2019-2021

Patent:

UF#-14344 entitled "Pharmacogenetics for the Identification of Risk Factors for Development of Jaw Osteonecrosis in Patients on Bisphosphonates" filed in September 2013

TEACHING

University of Florida

College of Pharmacy

Pharmacogenomics (PHA 6449)

2008-present. Course coordinator since 2013. Required graduate course. Delivered 6 lecture hours per semester on Pharmacogenomics to class size of 8~15.

Introduction to Quantitative Methods (PHA 5719)

2010-2015. Course Master. Required course for Second year Pharm.D students. Taught class sizes of 287 to 294. Delivered approximately 30 lecture hours per year on basics of biostatistics and literature evaluations as well as led 24 discussion sessions per year.

Interdisciplinary Family Health (BMS 6828/6829)

2008-2012. Facilitators for 12 first-year professional students per semester.

College of Medicine

Advances in Hypertension Research (GMS 6413)

2013-2016. Graduate course. Delivered 2 lecture hours per semester on Pharmacogenomics and hypertension to class size of 4~8.

SERVICE

PROFESSIONAL SERVICE

EDITORIAL BOARDS

Associate Editor: American Heart Journal Plus: Cardiology Research and Practice

2020-present

Clinical Translational Science

2018 - present

PLOS ONE

2011 - 2016

Journal of Pharmacovigilance

2013 – 2016

AD HOC GRANT REVIEWER

Deutsche Forschungsgemeinschaft, German Research Foundation 2021-present

The French National Cancer Institute 2022-present

MANUSCRIPT REFEREE:

American Journal of Cardiology

Clinical Cardiology

Clinical Pharmacology and Therapeutics

Clinical Epidemiology

Clinical Translational Science

Hypertension

Journal of the American College of Cardiology

Pharmacogenomics Journal
Pharmacogenomics
Pharmacotherapy
PLOS ONE
Medicine
The Annals of Pharmacotherapy Editorial Review
Gene and Nutrition
Circulation: Cardiovascular Genetics
Scientific Reports

PROFESSIONAL SOCIETIES AND ORGANIZATIONS

| | |
|----------------|--|
| 2001 - 2005 | Member, American Association of Pharmaceutical Scientists (AAPS) |
| 2004 - present | Member, American Society of Clinical Pharmacology and Therapeutics (ASCPT) |
| 2005 - present | Member, American Heart Association (AHA) |
| 2006 – 2010 | Member, International Society of Genetic Epidemiology (ISGE) |
| 2014 - present | Member, American Society of Human Genetics (ASHG) |
| 2015 – 2018 | Member, American Society of Bone and Mineral Research (ASBMR) |
| 2016 - present | Member, American College of Cardiology (ACC) |
| 2020- present | Member, Pharmacogenomic Research Network (PGRN) |
| 2021- present | Member, International Cardio-Oncology Society (ICOS) |

UNIVERSITY SERVICE

University of Florida

- Core member, UF Health Cancer Center Scientific Review and Monitoring Committee (SRMC), 2023-present
- Faculty advisor for student organization GradCru, 2020-present

College of Pharmacy

- Curriculum Assessment Committee, 2010-2016
- Faculty Search Committee, 2011-present
- Faculty advisor, 2011-present
- Admission Committee, 2014-2016
- Financial Aids/Scholarship Committee, 2016-2020
- Academic Professional and Standards Committee, 2023-present